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Abstract 
Amniotic fluid stem cells (AFSCs) offer therapeutic potential for prenatal and 
neonatal diseases based on their unique features. From the development of 
embryos, AFSCs represent a category between embryonic stem cells (ESCs) 
and mesenchymal stem cells (MSCs), with AFSCs more primitive than MSCs. 
Our lab has previously established that AFSCs can be reprogrammed to regain 
functional pluripotency with valproic acid (VPA). However, detailed mechanisms 
are still unknown. Here, our results showed that Wnt signalling was 
downregulated in the initial stage and upregulated with VPA treatment; whereas 
mesenchymal-to-epithelial transition (MET) was not observed in the process. 
Additionally, our previous results demonstrated that AFSCs maintained in ESC 
conditions shared 82% transcriptome similarity with ESCs. In the second part 
of this study, we revealed that features of AFSCs including marker expression 
and differentiation ability were sustained better in ESC conditions. Regarding 
osteogenesis, enhanced osteogenic ability was found in AFSCs maintained in 
ESC conditions due to a TGF-/CD73-dependent signalling pathway. Moreover, 
in addition to possessing the same tri-lineage differentiation capability as MSCs, 
AFSCs can also be induced to express cardiac markers, but contractile cells 
have not been obtained yet. As features of AFSCs are better preserved in ESC 
conditions, a Wnt-dependent cardiomyocyte differentiation protocol for 
pluripotent stem cells is examined on AFSCs in the last part of this study. Our 
results showed that, with the Wnt-dependent protocol, cardiac markers were 
induced but spontaneously contractile cells were not observed. Taken together, 
our findings show that (1) Wnt signalling may play a role in VPA-induced 
reprogramming, (2) AFSCs maintained in ESC conditions can better maintain 
stem cell features, especially osteogenic ability through a TGF-/CD73 pathway, 
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(3) With a Wnt-dependent protocol, AFSCs can be induced to express cardiac 
markers but not to become contractile cells.  
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General introduction of stem cells 
Stem cells contribute to every cell type of the body. When a human embryo is 
3 to 5 days old, the blastocoel is formed and the embryo is now termed a 
blastocyst (Fig. 1A). The inner cell mass of the blastocyst forms the entire 
structure of the fetus [1]. Stem cells support the development of the fetus into 
a mature body. In adults, stem cells function as a repair system by becoming 
specific cell types to replace diseased or damaged tissues [2]. This unique role 
will continue until the last day of life, albeit with lower efficiency.  
 
For stem cells to act as a constant repair system, distinctive characteristics are 
required. Self-renewal, through cell division, maintains the stem cell population 
[2, 3] and differentiation, in response to certain stimuli, allows stem cells to 
become specific functional cell types [2, 3] (Fig. 1B). These two key features 
distinguish stem cells from other cell types. Stem cells are sensitive to the 
environment. A complicated microenvironment regulates the balance between 
stem cell self-renewal and differentiation. Moreover, different types of stem cells 
require different environments to maintain their characteristics [4]. For example, 
a culture environment that is able to maintain self-renewal of adult stem cells 
could lead to differentiation of embryonic stem cells [5, 6]. These complexities 
make preserving stem cell properties in vitro challenging.  
 
The levels of activity of stem cells also vary between tissues. For example, stem 
cells self-renew and differentiate regularly in the bone marrow to maintain the 
blood cell population but only become active under certain circumstances, such 
as aging or damage, in the heart [7]. Additionally, the efficiency of stem cell self-
renewal and differentiation decreases with age, contributing to the poor levels 
19 
 
of recovery observed in older people following trauma [8, 9].  
 
In addition to the variation in stem cell activity among tissues, different sources 
also provide different types of stem cells. In 1981 and 1998, embryonic stem 
cells (ESCs) were isolated from the inner cell mass of early mouse [10] and 
human [11] embryos, respectively. ESCs are pluripotent, meaning that they are 
able to differentiate into all types of cells within the body [10, 11]. However, 
since ESCs are obtained from blastocysts, there are ethical issues associated 
with their isolation. Adult stem cells can be isolated from various tissues, such 
as bone marrow, fat tissue, and dental tissue [12-14] and thus have few ethical 
issues associated with their derivation. Adult stem cells have limited 
differentiation abilities, meaning that they are not capable of forming an entire 
body but only lineage-specific cell types [3, 12]. This property is known as 
multipotency. To overcome the restricted differentiation abilities of somatic stem 
cells and the ethical issues associated with ESCs, Yamanaka and his group 
established a way to generate pluripotent stem cells from somatic cells in 2006 
[15]. They demonstrated that somatic cells can be reprogrammed to induced 
pluripotent stem cells (iPSCs) by introducing four defined factors. The discovery 
of iPSCs not only addresses the ethical concerns associated with ESCs but 
may also provide advantages over the use of ESCs.  
 
Given their unique abilities, stem cells have numerous promising applications, 
such as cell therapy [16], tissue engineering [17], drug discovery [18] and 
development of personalized medicine [19]. However, most of these 
applications are still at the pre-clinical stage. 
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Figure 1 
A 
 
B 
 
Figure 1 General definitions of stem cells 
(A) Different potency of stem cells (pluripotent, multipotent, and unipotent). 
(Adapted from [20]) (B) Self-renewal and differentiation properties of stem cells.  
 
 
21 
 
1.1 Pluripotent stem cells 
Stem cells can be categorized according to their potency, which refers to their 
differentiation ability (Fig. 1A). For example, pluripotent stem cells have the 
capacity to become all cell types from each of the three germ layers, endoderm, 
mesoderm, and ectoderm [21]. Because of this unique ability, pluripotent stem 
cells have the most potential clinical applications compared to other stem cells. 
For example, instead of isolating hepatocytes from the liver, hepatocytes can 
be obtained via the differentiation of pluripotent stem cells [22]. Additionally, 
hepatocytes that have been isolated from liver tissue can only provide limited 
numbers of cells but the unlimited self-renewal capacity of pluripotent stem cells 
means that the number of hepatocytes that can be obtained from a pluripotent 
stem cell line is unlimited. This can be applied to all cell types of the human 
body.  
 
ESCs and iPSCs are the main types of pluripotent stem cells that have been 
described. They both fit the criteria of being pluripotent, including the ability to 
differentiate into the three germ layers and the expression of pluripotency-
associated markers, such as Oct-4, Nanog, Tra1-60, Tra1-81, SSEA1, SSEA4, 
KLF4 and Lin28 [1, 15, 23]. These factors contribute to maintaining pluripotent 
stem cells in an undifferentiated state and thus allowing them to self-renew and 
this needs to be accurately regulated. For instance, precise levels of expression 
of Oct-4 are required for the maintenance of pluripotency. In ESCs, increasing 
the expression of Oct-4 leads to the differentiation of pluripotent stem cells into 
endoderm and mesoderm, whereas decreasing Oct-4 expression results in 
trophoblast differentiation [24]. In addition to examining the expression of the 
pluripotent markers, the ability of cells to differentiate into the three germ layers 
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can be demonstrated by differentiation using the appropriate protocols, such as 
via the formation of embryoid bodies in vitro [25], or teratomas in vivo [11]. 
Although ESCs and iPSCs are both pluripotent, there are differences between 
them. These differences will be described in the following sections. 
  
1.1.1 Embryonic Stem Cells 
Upon their isolation from inner cell mass, ESCs were initially compared to 
embryonal carcinoma cells (ECCs), which demonstrated comparable 
properties to pluripotent stem cells [10]. For example, mouse ESCs were shown 
to have a similar epithelial-like morphology to ECCs. Additionally, mouse ESCs 
were able to perform in vitro differentiation into cell types from each of the three 
germ layers and formed teratomas in vivo [10]. The results indicated that cells 
isolated from the inner cell mass were pluripotent. However, since sustaining 
ESCs in vitro was challenging initially, mouse ESCs were maintained in the 
conditioned medium of ECCs therefore demonstrating that factors secreted by 
these cells were able to maintain pluripotency in ESCs [10]. With our developing 
knowledge of ESCs, defined culture conditions are now well established. Since 
ESCs are obtained from the inner cell mass of pre-implantation blastocysts, 
they have the ability to form embryos. Martin Evans and his team demonstrated 
that mouse ESCs were able to recolonize embryos and contribute to viable 
chimeras when injected back into developing embryos [26].  
 
In 1998, James Thomson and his group first established the isolation of human 
ESCs from in vitro fertilization (IVF) surplus blastocysts [11]. Human ESCs 
demonstrated the features of pluripotent stem cells such as expression of 
pluripotent markers including alkaline phosphatase, SSEA3, SSEA4, and Tra1-
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81 and teratoma formation upon injection into severe combined 
immunodeficient mice [11]. Moreover, human ESCs were capable of 
differentiating into the three germ layers in vitro as well. However, due to ethical 
issues, testing the ability of human ESCs to contribute to chimeras in vivo is not 
permitted. Therefore our ability to prove the pluripotency of human samples 
remains limited.  
 
1.1.1.1 Applications of ESCs 
ESCs have great promise for use in regenerative medicine. For instance, ESCs 
can be induced with growth factors to differentiate into insulin-producing cells, 
which could be used to replace the abnormal cells in type I diabetes. ESC-
derived cells have been shown to release insulin upon glucose stimulation and 
become vascularized in vivo when implanted into diabetic mice [27]. In addition 
to insulin-producing cells, neurons derived from ESCs have also demonstrated 
therapeutic benefits [28]. Transplantation of ESC-derived oligodendrocytes into 
spinal cord injury models, resulted in both differentiation into mature 
oligodendrocytes and some restoration of motor function and remyelination [29].  
 
In addition to their potential clinical applications, ESC-derived cells provide a 
platform for pre-clinical drug development [30]. Adverse effects on the heart are 
a major factor leading to the failure of drug development [31] and due to the 
lack of availability of human cardiomyocyte cell lines, preclinical studies are 
challenging. Although animal models can be applied to address this challenge, 
species variation may result in different response than in humans [31]. Human 
ESC-derived cardiomyocytes may be a suitable alternative to assess the 
adverse effect of the new compounds, therefore increasing the efficiency of the 
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development of new drugs [32]. Despite the promise of human ESCs, the 
ethical issues associated with their source remain a concern, since their 
derivation involves the destruction of human embryos. Various other potential 
sources with fewer ethical concerns have recently been reported, including 
induced pluripotent stem cells (iPSCs) [15, 23]. 
 
1.1.2 Cellular Reprogramming by Nuclear Transfer  
Human ESCs provide a promising source for developing treatments for various 
diseases but ethical challenges hamper their widespread therapeutic use. To 
avoid these ethical issues, cellular reprogramming techniques present an 
alternative approach to obtain pluripotent stem cells. Fertilization of egg by 
sperm is a nature reprogramming process, meaning that two non-pluripotent 
cells are able to be reprogrammed to pluripotent stage, and thus demonstrating 
that the fertilized egg is capable of releasing factors to trigger this process.  
 
Nuclear reprogramming, which involves transferring nuclei from differentiated 
cells into enucleated eggs in a second meiotic metaphase, provides a possible 
route for the generation of pluripotent stem cells [33-35]. Fusion of the somatic 
nucleus and enucleated egg is induced by electrical or chemical stimulation, 
which causes nuclear swelling and chromatin protein exchange and results in 
the reactivation of pluripotent genes such as Oct-4, Sox2 and Nanog [36]. The 
reprogrammed cells are then able to develop into blastocysts and contribute to 
embryonic development. Because the reprogrammed cells have the same 
genetic background as the donor nuclei, this approach provides the possibility 
of cloning. The generation of the first sexually mature adult frogs by nuclear 
transplant was achieved by Gurdon and his colleagues [37]. 40 years later, 
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Wilmut and his colleagues demonstrated the cloning of a mammal, Dolly the 
sheep, for the first time [35, 38]. By transferring a somatic nucleus into an 
enucleated oocyte, the resulting hybrid cells were able to implant and develop 
into an animal. These findings revealed that adult cells are able to be reversed 
to an early embryonic stage and contribute to embryonic development. 
Nevertheless, animals generated by cloning will suffer premature aging, 
meaning that they could develop diseases commonly found in the older animals 
[39]. Moreover, due to the ability of a nuclear reprogrammed egg to give rise to 
a human being, there are ethical concerns associated with their generation and 
use.  
 
1.1.3 Induced Pluripotent Stem Cells 
In addition to nuclear reprogramming, alternative sources of pluripotent stem 
cells can be generated by fusing somatic cells with ESCs or by exposing them 
to ESC extracts [40, 41], thus indicating that pluripotent stem cells contain 
elements that can reverse cell fate from terminally differentiated to an early 
embryonic stage. To reverse or maintain cell identity, accurate regulation of 
gene expression is essential. Transcription factors, such as Oct-4, can bind to 
the specific promoters and turn on the expression of target genes. However, 
during the development of an embryo, pluripotent genes are silenced as 
pluripotent stem cells differentiate into somatic cells, for example by chromatin 
remodelling such as methylation. Methylation restricts the binding of 
pluripotency-related transcription factors to the promoters of particular genes.  
 
Based on our knowledge of reprogramming by nuclear transfer and cell fusion, 
Yamanaka and his team hypothesized that by manipulating key pluripotency-
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associated transcription factors, pluripotency could be induced in somatic cells 
[15]. Twenty-four key pluripotency-related factors were selected and examined 
for a potential role in the reprogramming of somatic cells. In 2006, Yamanaka 
and his group reported that mouse somatic cells can be reprogrammed to 
pluripotency with the use of four defined factors, Oct4, Sox2, Klf4, and c-Myc 
[15]. They named these cells induced pluripotent stem cells (iPSCs). Mouse 
iPSCs closely resemble mouse ESCs in various respects. For example, they 
express endogenous pluripotent markers at the RNA and protein levels and the 
promoters of these pluripotency-related genes, such as Nanog, were 
demethylated, allowing their transcriptional regulation. Moreover, mouse iPSCs 
were able to form embryoid bodies in vitro and teratomas in vivo, both of which 
contained cells from each of the three germ layers. Additionally, mouse iPSCs 
contributed to the formation of chimeric mice when injected into developing 
embryos, indicating that they had regained functional pluripotency [15].  
 
A year later, in 2007, the same team demonstrated similar results with human 
somatic cells [23]. By inducing the expression of the same four factors, Oct-4, 
Sox2, Klf4 and c-Myc, human iPSCs were obtained. The pluripotency of these 
human iPSCs was demonstrated by their expression of pluripotent markers, 
such as Oct-4, Nanog, Tra1-60, and their formation of embryoid bodies in vitro 
and teratomas in vivo [23]. The discovery of human iPSCs has opened up a 
new era of pluripotent stem cell research. Prior to their discovery, ESCs were 
the only pluripotent stem cells but due to the ethical concerns, applications of 
ESCs are limited. Not only do iPSCs overcome these ethical issues, they also 
present new opportunities for use in disease modelling and personalized 
medicine, which makes it possible to understand the variation between patients 
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and to identify the most suitable medication for a particular individual [19, 42]. 
 
1.1.3.1 Challenges of iPSCs 
Although Yamanaka and his team have established that somatic cells can be 
reprogrammed to iPSCs with defined factors and without ethical issues, there 
are other concerns associated with iPSCs. For example, that tumorigenesis 
may result from the induction of the oncogene, c-Myc, and/or mutations that 
occur as a result of genomic integration. In order to address the safety issues 
associated with iPSCs, several strategies have been developed. Initially, 
retrovirus and lentivirus were used as delivery methods for the Yamanaka 
factors but these methods result in the integration of viral DNA into the genome. 
To avoid modification of the genome, a number of integration-free delivery 
methods have been introduced. For example, non-integrating viral vectors, 
such as adenovirus and Sendai-virus, have been shown to reprogram human 
somatic cells without integration [43, 44]. Moreover, the use of episomal vectors 
has been shown to effectively reprogram human fibroblasts [45].  
 
iPSCs have been obtained from somatic cells using Oct-4, Sox2, and Klf4 but 
in the absence of c-Myc [46]. The number of Yamanaka factors used can be 
reduced even further, to Oct-4 alone, by using neural stem cells (NSCs) that 
already express the other three factors [47]. Another reason for the ease of 
reprogramming of NSCs is likely due to the fact that they are already stem cells 
and therefore have less epigenetic barriers to reprogramming than terminally 
differentiated cells.[48]. Several other types of stem cells, such as 
hematopoietic stem cells and amniotic fluid stem cells, have also been 
reprogrammed without c-Myc [48, 49]. Although using integration-free methods 
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and excluding c-Myc can avoid concerns regarding tumorigenesis, the 
efficiency can be compromised using these methods. For example, yields of 
iPSC colonies were ten times fewer in the absence of c-Myc compared to when 
it was used as a reprogramming factor [50] and due to a low percentage of cells 
co-expressing the Yamanaka factors, with adenovirus method has been shown 
to be inefficient [43].  
 
In order to increase the efficiency of iPSC production with the safety-modified 
methods, chemical compounds have been used. A number of studies have 
demonstrated that chemical manipulation of the epigenetic state of a cell during 
the initial step of the reprogramming can enhance the iPSC production 
efficiency [51, 52]. Pluripotent stem cells and differentiated cells have been 
shown to differ greatly in their epigenetic status [53]. For example, the 
promoters of pluripotency-associated genes are hypomethylated in pluripotent 
stem cells but hypermethylated in somatic cells and methylation of pluripotency-
related promoters, such as Oct-4, by DNA methyltransferases is an initial step 
in differentiation and embryonic development [54]. Histone methyltransferase 
G9a is responsible for recruiting DNA methyltransferases to the Oct-4 promoter 
[55]. The important role of this enzyme in preventing pluripotency and 
promoting differentiation has been demonstrated by the observation that 
somatic cells can be reprogrammed five times more efficiently in the presence 
of an inhibitor of G9a, but in the absence of c-Myc. Additionally, the combination 
of a G9a inhibitor and an inhibitor of DNA methyltransferases has been shown 
to increase the efficiency by around 30 times compared to the efficiency 
observed in the absence of chemical compounds [51]. In addition to the role of 
methylation in reprogramming, other epigenetic regulators also contribute to 
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enhancing iPSC production. Valproic acid (VPA), a histone deacetylase 
inhibitor, has been reported to increase the efficiency of reprogramming by 
around 20 times in the absence of c-Myc [52, 56]. Together, these results 
indicate that epigenetic regulation is crucial for reprogramming. 
 
1.1.4 Reprogramming to pluripotency using chemicals 
In addition to epigenetic regulation, manipulating the cell signalling pathways 
involved in maintaining pluripotency has been shown to increase the efficiency 
of reprogramming as well. For example, inhibition of MEK and GSK3β have 
been shown to increase the efficiency of iPSC generation [57, 58]. In addition, 
chemical stimulation has been demonstrated to directly reprogram somatic 
cells to functional pluripotency without any Yamanaka factors [59]. Hou et al. 
have reported that mouse embryonic fibroblasts can be successfully 
reprogrammed by stimulation with Forskolin, 2-methyl-5-hydroxytryptamine, 
D4476, VPA, CHIR99021, 616452 and Tranylcypromine alone. Chemically-
reprogrammed pluripotent stem cells not only express pluripotent markers but 
are also able to differentiate into cell types from each of the three germ layers 
in vivo [59]. However, the chemical reprogramming of human somatic cells to 
pluripotency has not yet been reported.  
 
As mentioned previously, stem cells are easier to reprogram due to their 
epigenetic state [48]. Our lab has previously demonstrated that amniotic fluid 
stem cells can be reprogrammed by VPA alone, when cultured in pluripotent 
stem cell culture conditions. We demonstrated the expression of pluripotent 
markers in these cells in addition to the formation of embryoid bodies and 
teratomas [60, 61]. Small molecules are well defined and their effects can be 
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accurately manipulated by altering their concentration and the timing of their 
addition. Chemical reprogramming provides a promising alternative strategy to 
provide iPSCs. However, the process is currently time-consuming and lacks 
reproducibility in comparison to methods involving the use of transgenes. 
Moreover, whilst overcoming the concerns associated with transgene 
integration, the potential for chemical stimulation to induce genetic instability 
still needs to be further investigated.  
 
1.1.5 Lineage-specific conversion and reprogramming 
In addition to use of iPSCs, the direct conversion from one cell type to another 
or the reprogramming of a somatic cells to a lineage-specific stem cell provide 
alternative cell sources for regenerative medicine. Compared to iPSCs, these 
methods have the advantage of avoiding the pluripotent state, which carries the 
risk of tumorigenesis, and are usually more efficient. As in the case of iPSCs, 
lineage conversion was first discovered by the forced expression or ablation of 
key lineage-specific transcription factors identified in embryonic development 
[62]. For example, forcing the expression of MyoD in fibroblasts, chondroblasts, 
and epithelial cells can convert the cell lineage into myoblasts with the 
expression of myoblast markers such as α-actinin, troponin and myosin heavy 
chain. Moreover, converted myoblasts can fuse into myotubes and exhibit 
spontaneous contraction [63, 64]. In addition to myoblasts, cardiomyocytes, 
neurons and macrophages have all been generated by similar methods. Forced 
expression of Gata4, Mef2c, and Tbx5 has been shown to reprogram cardiac 
and dermal fibroblasts into cardiomyocyte-like cell types which exhibit 
endogenous expression of cardiac-specific markers and spontaneous 
contraction [65]. Upon exposure to Ascl1, Brn2 and Myt1l, embryonic and 
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postnatal fibroblasts adopt a neuronal phenotype, exhibiting synapses, the 
generation of action potentials, and the expression of neuron-specific markers 
[66]. Furthermore, functional macrophages can be generated from fibroblasts 
via forced expression of PU.1 and C/EBPα/β. Induced-macrophages exhibit a 
macrophage-like morphology along with the upregulation of macrophage-
specific markers and downregulation of fibroblast markers. Induced-
macrophages are able to phagocytose bacteria and respond to inflammatory 
stimulation [67].  
 
In addition to the conversion in vitro, cells can also be converted in vivo. For 
example, with the same factors used to convert fibroblasts into cardiomyocytes 
in vitro [65], non-myocytes can be reprogrammed into functional 
cardiomyocytes in vivo, with assembled sarcomeres, expression of cardiac 
markers and ventricular-like action potentials. Moreover, in vivo converted 
cardiomyocytes cause a reduction in infarct size and attenuated cardiac 
dysfunction in myocardial infarction models [68].  
 
However, converting one cell type to another still represents a challenge to 
generated sufficient numbers of cells required for clinical use. Converting 
somatic cells into lineage progenitor cells could potentially provide unlimited cell 
numbers. As described previously, iPSCs can be obtained with the use of only 
one Yamanaka factor, Oct-4. Using extra stimulation with specific cytokines 
along with ectopic expression of Oct-4, fibroblasts can be reprogrammed 
directly into blood progenitors, bypassing the pluripotent state. The induced 
cells were capable of giving rise to granulocytes, monocytes, megakaryocytes, 
and erythrocytes [69]. However, similar to the generation of iPSCs, delivering 
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transcription factors raises safety issues due to the potential for genomic 
integration. More recently, it has been established that cellular conversion can 
be achieved by chemical stimulation alone. For example, a combination of 
forskolin, ISX9, CHIR99021, and I-BET151 can convert fibroblasts directly into 
neurons. The converted cells exhibited neuron-specific markers, action 
potentials, and formation of functional synapses [70]. Although direct lineage-
specific conversion and reprogramming present an alternative way to provide 
cells for potential regenerative medicine applications, it remains challenging to 
generate sufficient numbers of cells. Further studies of lineage-specific 
reprogramming into progenitor cells will be required to fully exploit the benefits 
of chemical approaches.  
 
1.1.6 Applications of iPSCs 
1.1.6.1 Tissue engineering 
Perhaps the most notable advantage of iPSCs is the ability to generate patient-
specific pluripotent stem cells. Patient-specific iPSCs make personalized 
medicine, such as tissue engineering, drug screening, and cell therapy, 
possible. Although only a few clinical trials with iPSCs have been conducted, 
these pre-clinical studies provide promising results. For example, it has been 
established that 3D-printed extracellular matrix scaffolds can be seeded with 
iPSC-derived cardiomyocytes, smooth muscle cells, and endothelial cells. 
iPSC-seeded scaffolds were capable of spontaneous contraction with calcium 
transients. Moreover, cardiac function, infarct size, apoptosis and vascular 
density were rescued in myocardial infarction models after transplantation of 
the scaffolds [71]. In addition to the heart, iPSC-engineered liver has also been 
reported. Self-organized 3D iPSC liver buds expressed a comparable gene 
33 
 
profile to in vivo liver buds and were shown to be vascularized after 
transplantation. Proper protein production and drug metabolism were found in 
the transplanted iPSCs liver buds. Furthermore, the transplanted iPSC liver 
buds were shown to rescue the liver function in a liver failure model [72].  
 
1.1.6.2 Drug screening and development 
Different patient responses to the same treatment are common in clinics [73]. 
In vitro drug screening using a patient’s cells may therefore be exploited to 
overcome this challenge and prescribe the most effective treatment for a 
particular individual. However, somatic cells derived from the biopsy of patients 
can only provide limited numbers since they usually stop proliferating after 
several passages. On the other hand, patient-derived iPSCs are able to self-
renew indefinitely so can theoretically provide an unlimited cell source. Patient-
derived iPSCs can be used for in vitro disease modelling and to perform patient-
specific drug screening before the most effective treatment is identified. It has 
been reported that amyotrophic lateral sclerosis patient-derived iPSCs can be 
differentiated into neurons for drug screening. The authors found that anacardic 
acid can rescue the diseased motor neuron phenotype [74]. In addition to their 
uses in drug screening, patient-derived iPSCs also offer a platform for new drug 
discovery and toxicity testing [18, 75]. This could increase the success of drug 
discovery and decrease the cost of failure in the clinical phase. Liang and 
colleagues have demonstrated that patient iPSC-derived cardiomyocytes 
responded to known cardiotoxic compounds, which caused arrhythmias with 
early or delayed afterdepolarizations [76]. Together, these results indicate that 
iPSC-derived cardiomyocytes could be used to predict adverse drug responses 
during pharmaceutical development. 
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1.1.6.3 Disease modelling 
Increasing our understanding of various disease-causing mechanisms will 
increase the likelihood of developing suitable strategies to combat these 
diseases in the future. For example, patient-derived iPSCs can be applied in 
disease modelling to help achieve this [75]. By comparing endothelial cells 
differentiated from familial pulmonary arterial hypertension patient-derived 
iPSCs to control iPSCs, a decrease in BMPR2 activator expression and an 
increase in BMPR2 inhibitor expression were observed in patients’ samples, 
which led to reduced adhesion, migration, and angiogenesis. These findings 
identify potential targets for the development of therapeutic strategies [77].  
 
Furthermore, whilst clinical samples only allow the study of the mature form of 
the disease, patient-derived iPSCs allow the study of early stage disease 
progression, by observing any defects in the differentiation of the iPSCs to the 
cell type of interest [75, 78]. Kim et al. showed that reprogramming epithelial 
cells from pancreatic ductal adenocarcinoma followed by differentiating them 
back into pancreatic tissue could provide information on cancer development 
at an early stage. Proteomic studies revealed different networks between early 
and late stages during cancer development, providing potential targets for 
therapy and markers for diagnosis [78]. Disease modelling using patient-
derived iPSCs is best suited to diseases which have a single underlying genetic 
cause since they are early onset and have clear phenotypes. However, 
diseases that involve multiple gene mutations and/or environmental causes are 
generally late onset and have low penetrance and are more difficult to study in 
this way. Moreover, lineage specific differentiation protocols have not yet been 
well established for all cell types. Further studies will therefore be required to 
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optimize the use of patient-derived iPSCs in disease modelling.   
 
1.1.6.4 Cell therapy 
Another advantage of iPSCs is their potential for use as an autologous cell 
source in regenerative medicine [79, 80]. The lack of immunogenicity and 
functional transplantation of various iPSC-derived tissues has been reported by 
Wang and colleagues. For example, iPSC-derived skin, islet, and heart were 
transplanted into syngeneic recipient mice. Transplanted cells survived and 
were functional, repairing local tissue wounds, lowering glucose by producing 
insulin, and developed into contractile cardiomyocytes, respectively. Moreover, 
no infiltration of inflammatory cells in response to the transplanted iPSC-derived 
cells was observed [81]. However, some other studies showed that minor 
inflammatory cell infiltration was found after autologous transplantation with 
iPSCs [82].  
 
Sickle cell anaemia, caused by single gene mutation, is a hereditary blood 
disorder. The mutated gene was corrected in hematopoietic progenitors derived 
from iPSCs and the cells were autologous transplanted into a mouse model of 
the disease. The kidney defects and respiratory rate were rescued by this 
therapeutic transplantation [80]. In addition to sickle cell anaemia, Parkinson’s 
disease patient-derived iPSCs also demonstrated therapeutic benefits in 
animal models. Dopaminergic neurons generated from patient-derived iPSCs 
survived and were functional, rescuing methamphetamine-induced rotations in 
the brains [83].  
 
Until now, only small scale clinical trials have been conducted with iPSCs. 
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Patient-derived iPSCs were differentiated into retinal pigment epithelial cells 
followed by autologous transplantation into a patient with neovascular age-
related macular degeneration. The transplanted cells remained in situ and 
visual acuity showed no improvement or worsening one year after the 
transplantation [79]. Although there are still very limited clinical trials with iPSCs, 
pre-clinical results of iPSCs are promising for clinical applications in the near 
future.   
 
1.1.7 Differences between ESCs and iPSCs 
The discovery of iPSCs proves that cell fate can be reversed from a terminally 
differentiated stage to one representative of the beginning of embryonic 
development, by the conversion of somatic cells to an ESC-like state [15, 23]. 
Many studies have shown the similarities between iPSCs and ESCs, however, 
iPSCs are still distinguishable from ESCs in various respects [84, 85]. A pivotal 
step in reprogramming involves resetting the epigenetic landscape of somatic 
cells back to an ESC-like profile, by erasing the epigenetic markers of 
differentiation [86, 87]. Methylation generally results in gene silencing [88]. To 
maintain pluripotency, ESCs demonstrate a lack of methylation of various 
pluripotent genes, such as Oct-4 and Nanog [89]. During the later stages of 
embryonic development and cell differentiation, most of the pluripotent genes 
are methylated (switched off) and lineage-specific genes are switched on. A 
similar lack of methylation of pluripotency-associated genes can be observed 
in iPSCs when compared to ESCs [87, 90]. Nevertheless, differentially 
methylated regions (DMRs) between iPSCs and ESCs are still distinguishable 
[87]. The majority of DMRs have a similar methylation status in iPSCs to that of 
the original donor cells, a phenomenon known as epigenetic memory [91].  
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Epigenetic memory has been shown to influence the differentiation capacity of 
iPSCs [92]. For example, iPSCs often show delayed or lower efficiency of 
differentiation into various cell types, such as cardiomyocytes [93], neurons [94], 
and cells of the hematopoietic lineage [95], compared to ESCs. However, with 
the development of differentiation protocols, the differentiation potential of 
iPSCs has been shown to improve to a comparable level to ESCs in some cell 
types, such as cardiomyocytes [96]. For example, using a defined chemical 
differentiation protocol, cardiomyocyte differentiation from iPSCs showed 
similar efficiency to that of ESCs, with both giving rise to a homogenous 
population [96]. In addition, the epigenetic memory may confer an advantage 
on iPSCs whereby they exhibit an increased efficiency of differentiation into a 
particular lineage. [92].  
 
In addition to the effects on in vitro differentiation, epigenetic variation can 
affects the chimera formation ability of a cell line. The Dlk1-Dio3 locus on 
chromosome 12 in mouse iPSCs is commonly fully methylated, while only one 
allele is silenced in ESCs. iPSCs with a fully silenced Dkl1-Dio3 locus were 
shown to contribute poorly to the formation of chimeric animals. This effect 
could be rescued by histone deacetylase inhibitor treatment to reactivate the 
locus or by the isolation of iPSC clones exhibiting a similar methylation status 
to ESCs [97]. Although epigenetic memory makes iPSCs different from ESCs, 
it also provides potential markers for clonal selection of iPSCs. The similarities 
of iPSCs to ESCs mean that they offer enormous promise for various 
applications. However, the observation that iPSCs are not identical to ESCs in 
various respects should be taken into consideration. 
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1.2  Multipotent stem cells 
Multipotent stem cells have a more limited differentiation capacity than 
pluripotent stem cells; they are capable of differentiating into different cell types 
but only cell types within the same lineage. For example, multipotent 
hematopoietic stem cells can differentiate into various blood cell types, 
including lymphocytes, erythrocytes, monocytes, and neutrophils but cannot 
differentiate into hepatocytes or myocytes. However, some multipotent stem 
cells, such as mesenchymal stem cells (MSCs), have been reported to have a 
broader lineage differentiation ability [98, 99]. This will be further addressed in 
the following section. Multipotent stem cells are usually found in tissue or 
organs within which their primary role is to repair and maintain the function of 
the tissue by differentiation and self-renewal [3, 100]. They were first identified 
in the bone marrow, which contains both hematopoietic stem cells and 
mesenchymal stem cells [101, 102]. Hematopoietic stem cells were isolated 
first and recognized as the stem cells that supply blood cells to the body. MSCs, 
which were able to differentiate into bone, cartilage, and adipose tissues, were 
discovered at a later stage.  
 
Recent studies have reported various additional sources of MSCs in both adult 
and fetal tissues [3, 14, 103]. These fetal tissues include the amniotic fluid [103], 
amnion membrane [104], chorion membrane [105], placenta [106], cord blood 
[107], umbilical cord [108], and Wharton’s jelly [109]. In terms of adult tissues, 
besides the bone marrow, MSCs can be found in dental tissues [110], peripheral 
blood [111] and liver [112] as well. Since bone marrow-derived MSCs are the 
most well characterised and widely used in clinics, these cells are used as the 
‘gold standard’ for comparing MSCs from other sources against. However, 
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MSCs from different sources exhibit different features, including their marker 
expression and differentiation ability so it is challenging to obtain a single 
definition of MSCs. The minimum criteria to define MSCs has been introduced 
by the International Society for Cellular Therapy [113]. They propose that, as 
MSCs, cells must (a) adhere to plastic culture conditions, (b) express CD73, 
CD105, and CD90 and be negative for CD45, CD34, CD14, CD19, and HLA-
DR surface markers and (c) be able to differentiate into osteoblasts, adipocytes, 
and chondrocytes in vitro. Although MSCs from the various different sources 
exhibit unique characteristics, they all meet these minimal criteria.  
 
1.2.1 Isolating and maintaining MSCs 
In order to isolate MSCs from the various different sources, a range of methods 
have been demonstrated. In general, these methods depend on whether the 
tissue is solid or fluid. For fluid samples, such as amniotic fluid, bone marrow, 
and peripheral blood, MSCs can be isolated by density gradient centrifugation 
[114, 115] whereas with solid tissues such as adipose, dental tissues, and 
placenta, enzymatic digestion is necessary to obtain the MSC population [116, 
117]. MSCs isolated using either protocol are then plated onto tissue culture 
plastic and the adherent cells which meet the criteria set out by the International 
Society for Cellular Therapy, are then expanded for further analysis. This 
analysis is likely to include tri-lineage differentiation and the examination of 
marker expression to determine whether the cells meet the full MSC-defining 
criteria. Dulbecco’s modified Eagle’s media (DMEM) or alpha Minimum 
Essential Medium (alpha-MEM) with 10% fetal bovine serum are commonly 
used in order to maintain and expand MSCs in vitro. Growth factors, such as 
basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF), can 
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also be supplemented in the media to enhance cell growth [118-120].  
 
Although protocols for isolating MSCs from different sources have been well 
established, maintaining the characteristics of MSCs in vitro remains 
challenging. In order to use MSCs in the clinic, their proliferation and 
differentiation abilities must be adequately maintained in vitro using the 
appropriate conditions. As stem cells, MSCs are capable of self-renewal. 
However, the proliferation ability of MSCs declines over time in culture. Cellular 
senescence and short telomeres have been observed in late passage MSCs 
cultured in vitro in DMEM-based medium [121, 122]. These MSCs 
demonstrated morphological enlargement, decreases in MSC marker 
expression, and eventually growth in response to prolonged culture. 
Upregulation of micro-RNAs such as miRNA-371 and miRNA-29c, which 
regulate cell proliferation and senescence, were found in late passage MSCs 
[121]. Moreover, loss of multipotency has also been reported in these cells due 
to the accumulation of reactive oxygen species and dysregulation of 
differentiation factors [123, 124]. For example, an imbalance of Runx2 (an 
osteogenic factor) and PPARγ (an adipogenic factor) resulted in a shift in the 
differentiation preference of these cells [125]. These findings indicate that the 
current in vitro culture environment is not sufficient to preserve MSC properties 
long-term. To obtain MSCs with functional multipotency as required for clinical 
application, conditions that provide stable MSC characteristics will be essential. 
We investigate improved in vitro culture conditions for sustaining MSC 
properties in this study.  
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1.2.2 Differentiation abilities of MSCs 
MSCs were characterized as multipotent following their initial isolation from the 
bone marrow owing to their ability to give rise to three mesodermal lineages, 
osteogenic, chondrogenic and adipogenic [102, 126]. However, recent studies 
have revealed differentiation of MSCs into other types of mesodermal cells such 
as skeletal muscle, smooth muscle and cardiomyocytes. [107, 120, 127]. 
Nevertheless, MSC-derived muscle cells are not as functional as those isolated 
from muscle tissues. For example, although MSC-derived muscle cells were 
shown to express muscle-specific markers, spontaneous contractility, a key 
phenotype of fully-differentiated muscle cells, was not observed [120, 127]. 
Potential trans-differentiation into the other two germ layers, ectoderm and 
endoderm, has also been reported. MSCs have been shown to form neuron-
like cells which express neuronal markers such as neurogenin-1 and -III-
tubulin in response to growth factors such as platelet-derived growth factor, 
bFGF or EGF. [128, 129]. In addition, hepatocyte-like cell types can be derived 
from MSCs using defined protocols. Hepatocyte specific markers, such as 
albumin and -fetoprotein, have been observed in MSC-derived hepatocyte-
like cells. Moreover, transplantation of MSC-derived hepatocytes into animal 
liver injury models resulted in liver regeneration, inhibition of inflammation and 
improvement in the survival rate [130, 131]. Although trans-differentiation of 
MSCs into ectoderm and endoderm has been demonstrated, fully functional 
cells are yet to be obtained using the current protocols.  
 
Optimization of the differentiation protocols may lead to the generation of fully-
differentiated cells. However, it is possible that MSCs have lost their full 
differentiation capacity due to the use of sub-optimal in vitro culture conditions. 
42 
 
These findings demonstrate the broad differentiation potential of MSCs, 
however, the exploration of more appropriate conditions to maintain this 
differentiation potential is required and will be described in this study. 
 
1.2.3 Fetal MSCs 
Human MSCs were first isolated from bone marrow and have been considered 
as the ‘gold standard’ against which MSCs from other tissues are compared. 
Since then, many additional adult tissues have been reported to contain MSC 
populations, such as liver [112] and peripheral blood [111]. MSCs isolated from 
adult tissues show promise for clinical applications due to their differentiation 
and immunomodulatory abilities [98]. However, their limited in vitro proliferation 
capacity presents a challenge for cell therapy and tissue engineering 
applications which require large numbers of cells [132]. In addition to adult 
tissues, fetal tissues provide an alternative source of MSCs. MSCs isolated 
from fetal samples have been reported to have a greater proliferation capacity 
compared to adult MSCs [133]. Adult MSCs typically show 15-30 cell doublings 
before senescence whereas fetal MSCs show the potential to undergo 70 
population doublings without senescing [134]. Fetal MSCs have been shown to 
have longer telomeres and higher telomerase activity than adult MSCs and 
these features played a part in preventing cellular senescence [133]. Moreover, 
fetal tissues provide higher yields of stem cells compared to adult sources. 
MSCs comprise only a minor proportion of the total cells population of various 
tissues (0.0001%-0.01%) and this number decreases significantly with age, 
leading to a higher percentage of MSCs in fetal tissues. [135-137].  
   
Fetal MSCs meet the criteria set by bone marrow MSCs, including marker 
43 
 
expression (CD73, CD90, and CD105) and differentiation ability (osteocytes, 
adipocytes, and chondrocytes) [103, 116]. The presence of MSCs has been 
reported in various fetal tissues such as amniotic fluid [103], amnion membrane 
[104], cord blood [107] and placenta [116]. Unlike ESCs, most of these fetal 
tissues provide a source of stem cells at an early developmental stage without 
ethical issues, with the exception of fetal tissues that are made available 
through the termination of a pregnancy.  
 
As a result of being derived at this early developmental stage, fetal MSCs are 
considered to be more primitive than adult MSCs, and therefore representative 
of an intermediate phase between ESCs and adult MSCs. For example, fetal 
MSCs express various ESC markers such as SSEA-3 and Rex-1, which are 
negative in adult MSCs [60, 61, 133]. Less markers of lineage commitment are 
found in fetal MSCs in comparison to adult MSCs [138, 139]. In addition to the 
expression of pluripotency-associated markers, fetal MSCs demonstrate an 
improved differentiation ability in comparison to adult MSCs. Fetal MSCs have 
been reported to have better osteogenic differentiation abilities compared to 
adult MSCs both in vitro and in vivo [140, 141]. Greater von-Kossa staining, 
alkaline phosphatase activity, calcium deposition, and expression of osteogenic 
markers were found in fetal MSCs compared to adult MSCs. When MSCs on 
scaffolds were transplanted into the bones of immunodeficient mice, fetal MSCs 
showed more mineralization than adult MSCs [141]. Furthermore, factors 
secreted from fetal MSCs were able to induce higher levels of osteogenesis 
than adult MSCs. Levels of expression of alkaline phosphatase and osteogenic 
markers, and calcium deposition increased in vitro in response to the treatment 
with fetal MSC-secreted factors. Bone formation also improved in vivo [140]. 
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Taken together, these results suggest that the increased growth kinetics, better 
yields of MSCs, higher stem cell marker expression and enhanced 
differentiation abilities offer a better cell source of MSC from fetal samples than 
adult. 
 
1.2.4 Amniotic fluid stem cells  
Amniotic fluid stem cells (AFSCs), derived from amniocentesis, provide a 
potential source of stem cells. From a developmental point of view, AFSCs 
represent an intermediate stage between ESCs and MSCs, exhibiting greater 
self-renewal and differentiation capacities than MSCs but not to the extent of 
ESCs. AFSCs meet the definitions of MSCs, such as expression of MSC 
markers (CD73, CD90, and CD105) and tri-lineage differentiation potential 
(osteocytes, adipocytes, and chondrocytes). In addition to the features of MSCs, 
AFSCs have been reported to express some pluripotent markers, such as 
SSEA4 and Sox2 [61]. The expression of Oct-4, a key pluripotency-associated 
transcription factor, in AFSCs remains controversial, with both positive and 
negative results being described in the literature [142, 143]. Oct-4 has two 
isoforms, Oct-4A, a pluripotency regulator, and Oct-4B, which is not associated 
with pluripotency. However, non-specific Oct-4A/B antibodies have mostly been 
used for detection of Oct-4 expression, resulting in false positive results. Our 
lab has demonstrated that, when Oct-4A-specific antibodies, are used, AFSCs 
are shown to be Oct-4A negative but that these cells are positive for Oct-4B 
(unpublished work), which is likely to explain the discrepancies in the literature 
[144, 145]. High telomerase activity and proliferation capacities have also been 
reported in AFSCs [61].  
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Moreover, AFSCs exhibit not only the tri-lineage differentiation capacity shown 
by all MSCs but have also been shown to differentiate into cell types that 
express renal and neurogenic markers [146, 147]. However, unlike the cells 
derived from tri-lineage differentiation of MSCs, AFSC-derived renal and 
neuronal cells are not fully functional. Nevertheless, even with the expression 
of some ESC markers and partial trans-lineage differentiation, AFSCs are not 
pluripotent, since they fail to form teratomas in immunocompromised mice and 
cannot contribute to chimeras [103]. The tumorigenic capacity of pluripotent 
stem cells is one of the major issues in their clinical application. Therefore the 
broad differentiation capacity of AFSCs in combination with their lack of 
tumorigenesis confers advantages on AFSCs over pluripotent stem cells as a 
cell source for clinical use. 
 
1.2.4.1 Heterogeneity of amniotic fluid stem cells 
Amniotic fluid (AF) is the protective liquid that surrounds the developing fetus 
in the amniotic sac, which has been widely used in genetic prenatal diagnosis 
of disorders such as Down syndrome, between 15 to 22 weeks of gestation. 
Although AF-derived cells are used in prenatal diagnosis, little is known about 
the detail of the heterogeneous cell populations that the AF contains. It has 
been reported that two major types of cells can be found in amniocentesis 
samples, including round-shaped (epithelial-like) and spindle-shaped 
(fibroblast-like) populations [148, 149]. Spindle-shaped cells are believed to be 
derived from the fetal membranes or trophoblast, due to their production of 
human chorionic gonadotropin and progesterone. Fetal skin has been 
suggested to be the source of the round-shaped cells. As a fluid sample, AF-
derived cells can be pelleted by centrifugation and then plated on tissue culture 
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plastic for further analysis of their MSC features. Spindle-shaped amniotic fluid 
stem cells (SS-AFSCs) and round-shaped amniotic fluid stem cells (RS-AFSCs) 
can both attach to tissue culture plastic and be maintained in culture [149]. 
Although SS-AFSCs are better characterized, in recent studies, RS-AFSCs 
have been isolated and shown to exhibit various MSC properties [145, 149, 
150]. Thus, AF is a promising source of stem cells for investigative and 
therapeutic use. 
 
1.2.4.2 AFSC culture conditions 
Although the isolation of cells from AF for prenatal diagnosis is well established, 
protocols for isolating and maintaining AFSCs in vitro have not yet been fully 
standardized. Various methods and conditions for isolating AFSCs with similar 
characteristics have been demonstrated, however, the consistency of the cell 
preparations remains uncertain. Since AFSCs are heterogeneous populations, 
AFSC populations isolated using different methods and conditions are likely to 
vary.  
 
Modified Eagle’s Medium (MEM) and alpha Minimum Essential Medium (MEM) 
are the most common basal media used to maintain AFSCs in vitro and are 
often supplemented with bFGF and/or EGF. Arnhold et al. showed that AFSCs 
maintained in either MEM or MEM with fetal bovine serum (FBS) 
demonstrated different cellular morphologies, SS and RS respectively. SS-
AFSCs were shown to have a more homogenous population doubling time, 
along with better osteogenic and chondrogenic differentiation capacities than 
RS-AFSCs whereas higher expression levels of the early neuronal marker 
HNK-1 were found in RS-AFSCs than SS-AFSCs after induced differentiation 
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[151]. In the presence of supplements such as bFGF, EGF, and Chang medium, 
in MEM or MEM, AFSCs showed higher growth kinetics and demonstrated 
similar expression of markers, however, their differentiation abilities were found 
to differ to those observed in DMEM-based medium. For example, the addition 
of bFGF increased the levels of osteogenesis, whereas improved levels of 
endothelial differentiation were observed in response to EGF stimulation [152].  
 
In addition to variations in the media used for maintaining AFSCs in vitro, the 
types of culture dishes used vary between different studies. For example, non-
tissue culture treated and tissue culture treated dishes have both been reported 
to be used for AFSC culture [61, 103, 153]. Although significant phenotypic 
changes of AFSCs are not reported using these two methods, it may still be 
possible to isolate different populations from AFSCs with different attachment 
properties by varying the type of culture plastic used. The optimal conditions 
required to isolate and maintain AFSCs are yet to be standardized. Although 
AFSCs cultured under the current conditions meet the criteria set by bone 
marrow MSCs, variation in marker expression and differentiation abilities still 
need to be taken into consideration before cells are used for further applications.  
 
In addition to optimizing AFSC culture conditions, sorting a specific population 
from the heterogeneous AFSCs may aid the generation of a homogenous cell 
population. De Coppi and colleagues found that c-Kit positive AFSCs were 
positive for SSEA4, a pluripotent/early embryonic developmental marker, and 
were able to differentiate into multiple lineages as evidenced by the expression 
of lineage-specific markers [103], however, Guan et al. found the same 
population to be negative for SSEA4 under the same culture conditions [153]. 
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c-Kit is only expressed by a low percentage of fresh/early passage of AFSCs, 
declining rapidly in vitro [154-156]. Sorting the c-Kit positive population from 
AFSCs is still controversial. Various studies have shown that AFSCs, with or 
without c-Kit sorting, meet the criteria of bone marrow MSCs [103, 149]. 
However, unsorted AFSCs have been shown to exhibit different expression 
levels of stem cell markers and better differentiation ability towards the neuronal 
lineage compared to the c-Kit sorted group [151, 152]. These findings indicate 
the heterogeneity of stem cell populations in AF, showing that there might be 
more than one type of stem cells in the AF. Since AF contains cell types from 
the early stages of development, it is likely to contain numerous stem cell types. 
However, further studies are needed to establish the optimal conditions for each 
of the different populations of stem cells in AF.      
 
1.2.5 Applications of AFSCs 
Regenerative medicine is rapidly expanding with the development of new 
technologies and our understanding of stem cells. Cell therapies and tissue 
engineering are two of the main approaches to repair damaged tissues. 
Although AFSCs are not yet in clinical use, pre-clinical studies have 
documented the various potential therapeutic applications of AFSCs. 
 
1.2.5.1 Cardiomyocyte differentiation of AFSCs 
Differentiation of AFSCs into various cell types, including cardiomyocytes has 
been documented in numerous studies. Several different cardiomyocyte 
induction conditions have been reported. Direct co-culture of AFSCs with 
neonatal rat ventricular myocytes (NRVMs) was first tested. AFSCs labelled 
with cell tracker were co-cultured at a 1:4 ratio with NRVMs for 10 days. 
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Following this incubation period, 5% of AFSCs were found to be positive for 
cardiac troponin T (cTnT) and to exhibit sarcomere-like structures [157]. Other 
studies found the expression of gap junctions, -actinin, and myosin heavy 
chain under these co-culture conditions as well [142, 153, 158]. However, using 
this co-culture system, the AFSCs expressing cardiac markers were frequently 
found to be bi-nuclear, thus raising concerns regarding the fusion of AFSCs 
and NRVMs. Cell fusion could result in false positive results being obtained.  
 
In addition to the co-culture system, attempts were made to induce 
cardiomyocyte differentiation in AFSCs by exposure to medium conditioned by 
NRVMs. However, cardiac marker expression was not observed under these 
culture conditions [157-159]. Chemical induction of cardiomyocyte 
differentiation of AFSCs has been demonstrated. AFSCs stimulated with 5-aza-
2’deoxycytidine (5-aza) for 24 hours followed by 10 days additional cell culture 
showed a gradual increase in the expression of cardiac troponin at both the 
transcriptional and translational levels. However, sarcomere formation did not 
occur [153] and spontaneous contraction was not observed in these cells. Thus, 
although AFSCs show potential for in vitro cardiac differentiation, further studies 
will be necessary to define the precise conditions required to induce the 
generation of fully-differentiated cardiomyocytes from AFSCs. 
 
1.2.5.2 Engineering heart tissue using AFSCs 
Due to their in vitro cardiac differentiation abilities, AFSCs represent a potential 
cell source for heart tissue engineering. Congenital heart disease is one of the 
leading causes of death in stillborn and newborn babies and surgery using 
biomaterials is usually necessary to repair the defects in those that survive. This 
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has involved the use of both synthetic and decellularized-tissue scaffolds [120]. 
Seeding stem cells onto a scaffold provides an ideal material for replacing the 
defective tissue and various different types of stem cells have been used in this 
way. For example, vascular grafts have been tissue engineered using 
autologous bone marrow MSCs and applied in clinical trials. These grafts 
survived and showed no signs of immunorejection [160].  
 
Nevertheless, isolating bone marrow from neonates is difficult and risky. iPSCs 
are another potential cell source for autologous transplantation but the risk of 
tumorigenesis remains a concern. AFSCs, on the other hand, with cardiac 
differentiation potential, better growth kinetics than adult MSCs, and without 
tumorigenic potential, may be better candidates for prenatal and neonatal tissue 
engineering. Additionally, collecting AF is a low-risk and well-established 
clinical procedure. AFSCs provide the additional advantage of being able to 
generate autologous tissue-engineered materials even before birth. For 
example, several studies have shown that AFSCs were capable of repopulating 
scaffolds and repairing tissues such as the heart valve [17, 161]. Weber et al. 
demonstrated functional heart valve repair in animal models upon 
transplantation of autologous AFSC-seeded biodegradable scaffolds. The 
engineered heart valve showed intact valvular integrity and no thrombus 
formation [17]. In another study, Schmidt et al. showed that their AFSC-seeded 
engineered heart valve was functional after a month of in vitro culture. The 
engineered heart valve exhibited the production of an extracellular matrix and 
demonstrated appropriate opening and closing behaviour [161].  
 
In summary, AFSCs have been shown to have the capacity to be used in heart 
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tissue engineering, this finding has promising implications for prenatal and 
neonatal autologous transplantation.       
  
1.2.5.3 The use of AFSCs in cell therapy for cardiac disease  
In addition to their potential use in heart tissue engineering, AFSCs may have 
potential for cell therapy to treat heart diseases too. MSCs from various sources 
have been demonstrated to have cardioregenerative abilities, either by 
differentiation or via their paracrine effects on the surrounding niche [162]. Bone 
marrow MSCs have even been evaluated in clinics. Patients with autologous 
intramyocardial injection of MSCs showed enhancements in systolic wall 
thickness, exercise capacity and regeneration of damaged myocardial tissue in 
the left ventricle [163].  
 
Although AFSCs are not yet in clinical use, pre-clinical studies have 
demonstrated promising results. As described in the previous section, fetal 
MSCs are more primitive than adult MSCs and, as such, have several 
advantages over these cells, such as higher growth kinetics and an improved 
differentiation capacity. Moreover, it is likely to be easier and safer to obtain 
fetal stem cell populations. AFSCs have been shown to improve cardiac 
function upon direct injection of the cells into the infarcted heart. Lee and 
colleagues showed that direct intramyocardial injection of AFSCs into 
myocardial infarction (MI) animal models attenuated the progression of heart 
failure, increased the wall motion and regenerated functional heart tissue. 
Moreover, the AFSCs were shown to differentiate into endothelial and smooth 
muscle cells and the expression of vascular growth factors, such as basic 
fibroblast growth factor and vascular endothelial growth factor, increased 
52 
 
significantly at the infarct site [164]. Bollini et al. have demonstrated similar 
results indicating that AFSCs improved heart function in MI models via 
paracrine effects. Their results showed that injecting AFSCs or their conditioned 
medium enhanced cell survival and decreased the infarct size. Actin monomer-
binding protein thymosin 4, a cardioprotective factor, was identified in the 
conditioned medium, suggesting a potential candidate for the therapeutic 
paracrine effects [165].  
 
The potential applications of AFSCs in cardiac disease have been studied 
widely. The findings show promising results, especially in in vivo models. 
However, the molecular mechanisms underlying both their in vitro 
differentiation and their in vivo therapeutic effects remain unclear. Functional, 
contracting AFSC-derived cardiomyocytes are yet to be observed, leading to 
concerns regarding the ability of AFSCs to differentiate into cardiomyocytes, 
both in vitro and in vivo. These concerns will be addressed in this study, with 
the aim of gaining a greater understanding of the cardiac differentiation 
capabilities of AFSCs. 
 
1.2.5.4 Osteogenic differentiation of AFSCs 
In addition to cardiac differentiation, as MSCs, AFSCs have the capability to 
differentiate into osteocytes. Their functional osteogenic differentiation ability 
makes AFSCs a promising cell source for repairing bone defects, caused by 
disease or trauma. MSCs are known to act as a natural repair system during 
bone growth and remodelling in vivo. In vitro, osteogenic differentiation from 
MSCs has been well documented and involves the use of factors such as L-
ascorbic acid, beta-glycerophosphate, and dexamethasone. We and others 
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have shown that using the standard osteogenic differentiation medium, AFSCs 
were able to express osteogenic markers, such as collagen1, osteocalcin, and 
osteopontin, and deposit calcium [145, 166]. However, the concentration of the 
components varies between labs. Other factors have also been reported to 
increase the osteogenic differentiation efficiency of AFSCs, such as 
Simvastatin [167] and phytoestrogens [168]. In the presence of these factors, 
AFSCs were induced to express osteogenic markers such as osteocalcin, 
osteopontin, collagen1 and Runx2 and showed positive alizarin red staining 
indicating the deposition of calcium from differentiated AFSCs. In addition to 
their in vitro osteogenic differentiation capabilities, MSCs (generally bone 
marrow MSCs) are currently under assessment in various clinical trials 
targeting a range of disorders, including bone defects [169], thus indicating the 
potential of these disorders to be treated with AFSCs in the future.  
 
1.2.5.5 The use of AFSCs in bone engineering 
Similar to cardiac tissue, bone has been shown to be engineered by AFSCs in 
vitro. This finding may be beneficial for the treatment of congenital bone defects 
in neonates. AFSCs not only provide autologous treatment opportunities but 
also possess improved growth kinetics and better differentiation abilities 
compared to adult MSCs [103]. Both synthetic and non-synthetic scaffolds have 
been widely studied. The principle of the scaffolds is to provide an environment 
mimicking the in vivo niche therefore helping seeded cells to form a functional 
tissue. Non-synthetic scaffolds, generated from natural compounds, provide 
various benefits including biological plasticity, biocompatibility and a lack of 
toxicity. For example, collagens, the main component of bone, have been 
widely used as non-synthetic scaffolds [170, 171]. By seeding AFSCs onto 
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collagen-based scaffolds followed by their transplantation to in vivo models, 
AFSC-seeded scaffolds showed faster regeneration ability, including higher 
mineralized tissue volume, than control groups. Authors also found that AFSCs 
were not only involved in bone regeneration but in promoting new vessel 
formation within the scaffolds [171].  
 
AFSCs showed a similar ability to form bone when seeded onto synthetic 
scaffolds. Peister et al. demonstrated that upon seeding AFSCs onto medical-
grade poly--caprolactone, mineralization was observed both in in vitro and in 
vivo by micro computed tomography, suggesting that AFSCs could be an 
effective cell source for bone engineering [172]. AFSCs not only showed better 
osteogenic differentiation in vitro compared to adult MSCs but demonstrated 
better mineralized matrix in scaffolds. Mineralization continued up to 15 weeks 
in the AFSC-seeded scaffolds but decreased from 5 weeks in the adult MSC-
seeded scaffolds [173]. Additionally, Mirabella and colleagues showed that 
AFSCs functioned as niche regulators, attracting endogenous cell homing to 
the damaged site for both bone and vessel regeneration [174]. Various studies 
have demonstrated the potential use of AFSCs in bone tissue engineering but 
since AFSCs play multiple roles inside scaffolds in vivo, further studies to 
understand their detailed mechanisms of action are required.  
 
1.2.5.6 Cell therapy for Bone Defects with AFSCs 
Self-regeneration repairs injured tissues in vivo. Stem cells play a vital role in 
this regeneration, including by differentiating into the required cell types and 
regulating the niche in the injured site by secreting numerous factors and 
recruiting more supportive cells to the site. The capacity of AFSCs to be used 
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as a source of cells for therapeutic use, including in bone defects, has been 
demonstrated [166].  
 
Osteogenesis imperfecta (OI), a genetic disorder caused by mutations in the 
collagen gene, leads to fragile bones that break easily. Several studies have 
shown that prenatal or neonatal transplantation of MSCs improved bone 
strength and reduced bone fractures in animal models of OI [175-177]. Guillot 
and colleagues transplanted MSCs from fetal blood into prenatal animal OI 
models and found that the frequency of long bone fractures reduced 
significantly along with increased bone strength, thickness, length, and 
mineralization. Donor cells were shown to express osteoblast lineage markers, 
indicating their in vivo differentiation ability [176]. Recently, Ranzoni and 
colleagues in our lab demonstrated that transplanting AFSCs into mouse 
neonatal OI models reduced the bone fracture rate and increased bone strength 
and quality. Additionally, the transplanted AFSCs were shown to differentiate 
into osteoblasts, promote endogenous osteoblasts maturation and reduce 
inflammatory signalling, such as transforming growth factor beta (TGF-β) [166].  
 
AFSCs are not yet in clinical use to treat bone defects but other MSCs, such as 
adult bone marrow MSCs and fetal liver MSCs, have been examined clinically 
in various prenatal and neonatal conditions [16]. For example, Horwitz et al. 
transplanted allogeneic bone marrow MSCs into children with OI. They 
observed new trabecular bone formation and increases in bone mineral content 
and growth velocity, in addition to a reduction in the frequencies of bone 
fractures in patients [169]. In addition to neonatal treatment with MSCs, prenatal 
treatment has been established as well [16, 178]. A fetus was transplanted with 
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allogenic fetal liver-derived MSCs at 31 weeks of gestation resulting in no 
further fractures during infancy. Immunoreactivity towards the transplanted cells 
was not observed [16]. However, the mechanisms by which MSCs repair bone 
defects in vivo, either by direct osteogenesis or paracrine effects, remain 
unclear. Most studies showed that donor MSCs underwent osteogenesis after 
transplantation but some demonstrated that MSCs did not engraft in the host 
bone, instead repairing the damaged bone tissue by secreting growth factors 
[179]. Since MSCs from different sources, both adult and fetal, demonstrate 
bone repair potential in animal models and patients, these findings demonstrate 
the potential of AFSCs for autologous cell therapy in the future.      
 
Aims of the study 
Due to the primitive nature of AFSCs, three major questions about their 
capabilities are addressed within this study: 
1. Our lab has previously demonstrated that AFSCs can be chemically 
reprogrammed to functional pluripotency without the need for transgene 
expression [60, 61]. However, the detailed mechanism by which this occurs 
remains unknown. To further our understanding of chemically-induced 
AFSC reprogramming, the potential signalling pathways involved in this 
process will be explored.  
2. The optimal in vitro culture conditions under which AFSCs should be 
maintained remain to be standardized and the conditions applied to date are 
only suitable for sustaining MSCs but not ESCs. Since AFSCs represent an 
intermediate stage between MSCs and ESCs, we will address the question 
of whether ESC conditions can maintain the primitive features of AFSCs to 
a higher degree than the MSC conditions most commonly used, including 
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osteogenic differentiation.  
3. The potential of AFSCs to differentiate into cardiomyocyte-like cell types has 
been demonstrated both in vitro and in vivo. However, spontaneous 
contraction is yet to be observed in these cells. On the other hand, the 
protocol to differentiate pluripotent stem cells into fully differentiated 
cardiomyocytes is well established [96]. Here, we ask whether AFSCs can 
be differentiated into functional cardiomyocytes through the use of the 
pluripotent stem cell cardiomyocyte differentiation protocol. 
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Chapter 2 
 
Potential Mechanism of VPA-Induced 
AFSCs Reprogramming  
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Introduction 
Yamanaka and his team have established that somatic cells can be 
reprogrammed to induced pluripotent stem cells (iPSCs) via the expression of 
four defined factors, Oct4, Sox2, Klf4 and c-Myc [15, 23]. iPSCs demonstrate 
similar characteristics to embryonic stem cells (ESCs), including the expression 
of pluripotency-associated markers and differentiation into cell types from each 
of the three germ layers in the form of embryoid bodies, teratomas and 
chimeras [15, 23]. Whilst being functionally equivalent to ESCs, iPSCs provide 
an advantage over ESCs in that their derivation is free from ethical issues. 
However, there are still concerns regarding the iPSC reprogramming process, 
for example the low efficiency and risks of genomic integration and oncogenic 
transformation associated with the process [180, 181]. Several studies have 
established different approaches to avoid these concerns, such as using 
chemicals to increase the efficiency of reprogramming, excluding c-Myc from 
the reprogramming factors and using non-integrating virus or recombinant 
proteins to evade potential genome modification [49, 59, 181]. However, further 
studies exploring the efficiency of, and safety issues surrounding iPSC 
reprogramming are still required.   
  
Since AFSCs represent an intermediate phenotype between ESCs and 
mesenchymal stem cells (MSCs) and are developmentally primitive, they might 
be easier to reprogram, for example with the use of fewer genetic factors or by 
manipulating culture conditions alone. Studies have shown that AFSCs can be 
reprogrammed with one ‘Yamanaka factor’ alone, Oct-4 [49], and that the 
reprogramming efficiency of these cells is much higher than that of adult cells 
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[182]. In addition to regulating transcription factors, manipulating signalling 
pathways can result in full cellular reprogramming. For example, stimulation of 
mouse somatic cells with seven different small molecule compounds, including 
valproic acid (VPA), in the absence of the Yamanaka’s factors, has been shown 
to be sufficient to reprogram them to pluripotency [59]. Moreover, our group has 
previously shown that AFSCs can be chemically reprogrammed to functional 
pluripotency, meaning the cells have regained the ability to differentiate into cell 
types from different germ layer [60, 61]. Our results showed that maintaining 
AFSCs under pluripotent culture conditions (maintaining cells in a Matrigel-
coated dish with Nutristem media, i.e. Nutristem+Matrigel) for 5 days prior to 
the stimulation of VPA for 5 days can successfully reprogram AFSCs into 
chemical iPSCs (CiPSCs). CiPSCs can be stabilized and maintained in culture 
for over 2 months. CiPSCs not only express pluripotent markers such as Tra1-
60, Rex1, and DNMT3b, which define bona fide reprogrammed cells, but also 
have the ability to form embryoid bodies in vitro and teratomas in vivo 
containing cell types expressing markers from different germ layers. In addition, 
CiPSCs were able to differentiate into definitive endoderm, neurons, 
oligodendrocytes, and hepatocytes [60, 61]. This simple and transgene-free 
method provides an ideal approach to generate safer iPSCs for potential clinical 
applications. However, the detailed mechanism of how VPA induces 
pluripotency in AFSCs remains unclear. Fully understanding the mechanism(s) 
involved in VPA-induced reprogramming of AFSCs will not only allow further 
optimisation of the protocol to achieve higher reproducibility and efficiency but 
also reveal the factors that are likely to improve the quality of the iPSCs 
generated using Yamanaka’s protocol.  
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Numerous studies have unveiled the mechanisms of how the Yamanaka factors 
reprogram somatic cells to pluripotency, through various molecular 
mechanisms including epigenetic, microRNA and signalling pathway-related 
mechanisms. For example, it’s now known that somatic cells must erase their 
original epigenetic landscape and convert to a pluripotent epigenome. This 
process involves DNA demethylation and histone re-modifications. 
Overexpression of microRNAs, such as the miRNA cluster 302-367, enhances 
mesenchymal-to-epithelial transition (MET), a key step of cellular 
reprogramming [183]. Moreover, manipulating the epigenome and microRNA 
expression results in activation or inhibition of different signalling pathways. For 
instance, Wnt signalling has been reported to play a part in the cellular 
reprogramming. The Wnt pathway widely regulates multiple cellular responses, 
including cell proliferation, migration, and differentiation. The role of Wnt 
signalling was first characterised in carcinogenesis [184]. Generally, the Wnt 
signalling pathway can be categorized into two branches, the canonical Wnt 
signalling pathway which involves -catenin protein, and the non-canonical Wnt 
signalling pathway which is independent of -catenin. When the canonical Wnt 
pathway is inactivated, -catenin binds to the GSK3β protein complex, leading 
to phosphorylation of -catenin followed by degradation. On the other hand, 
activation of the canonical Wnt pathway release -catenin from the GSK3β 
protein complex, allowing -catenin translocating into the nucleus to regulate 
downstream targets (Fig. 2.1). Roles for the canonical Wnt pathway in both 
maintaining pluripotency and cellular reprogramming of both mouse and human 
ESCs have been well established [185-189] . Activation of canonical Wnt 
signalling in the initial stage of reprogramming resulted in the earlier and more 
homogenous formation of ESC-like colonies compared to the control. Moreover, 
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this effect was blocked by ICG-001, a specific inhibitor of the canonical Wnt 
pathway [185]. Cellular reprogramming can be divided into early and late stages 
[190-193], within which Wnt signalling plays distinct roles. For example, 
inhibition of Wnt signalling at the early stages of reprogramming (day 0 to day 
3) promotes the expression of Nanog, a pluripotent marker necessary for 
reprogramming, therefore resulting in colony formation and activation of Wnt at 
this early stage blocked Nanog-positive colony formation. On the other hand, 
inhibiting Wnt signalling at the later stages (day 6 to day 9) prevented the 
formation of Nanog-positive colonies, whereas activating Wnt signalling at this 
stage promoted Nanog-positive colony formation [190]. Since Wnt signalling is 
pivotal in iPSC reprogramming, the role of Wnt in VPA-induced reprogramming 
of AFSCs will be investigated in this study.     
 
In addition to the role of signalling pathways, cellular morphological changes 
play important roles in reprogramming too. ESCs are considered to have an 
epithelial morphology due to their expression of epithelial markers and 
formation of cell-cell contacts via adhesion molecules such as E-cadherin. On 
the other hand, mesenchymal cells such as fibroblasts express N-cadherin and 
exhibit looser cell-cell contacts. Mesenchymal-to-epithelial transition (MET) is 
therefore an important step in the initial stages of iPSC reprogramming [193]. 
Previous studies have documented that mesenchymal markers such as N-
cadherin, Snail, and Fibronectin are down regulated during the early stages of 
iPSC reprogramming whereas epithelial markers such as E-cadherin, Ep-CAM, 
and DSP are upregulated [194]. In addition, blocking MET signalling decreases 
the efficiency of iPSC reprogramming. By introducing TGF-1, which induces 
63 
 
epithelial-to-mesenchymal transition (EMT), into the reprogramming process, 
inhibition of epithelial marker expression and upregulation of mesenchymal 
marker expression was observed [194]. Furthermore, expression of Oct4 plays 
an important role in the reprogramming process. VPA has been shown to 
enhance Oct4 promoter activity via the PI3K/AKT/mTOR pathway [195, 196], 
suggesting another possible mechanism by which VPA induces AFSCs 
reprogramming. 
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Figure 2.1 
 
Figure 2.1 
Schematic diagram of canonical Wnt signalling.  
Activation of canonical Wnt signalling (left) and inactivation of canonical Wnt 
signalling (right).  
 
Aims 
Our lab has previously demonstrated that AFSCs can be reprogrammed to 
CiPSCs without the introduction of exogenous factors. However, the detailed 
mechanism by which this occurs remains unclear. Since Wnt signalling and 
MET play vital roles in iPSC reprogramming, we will examine the role of these 
signalling pathways in VPA-induced AFSCs reprogramming. 
 
 
 
65 
 
Materials and Methods 
AFSCs isolation and culture 
Frozen AFSCs samples collected by a previous lab member were used in this 
section. Frozen cells were thawed in a water bath and transferred to 5 ml of 
MSC medium (Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) (Biosera), 2 mM L-Glutamine, 
50 IU/ml penicillin and 50 mg/ml streptomycin (Gibco-BRL). Cell pellets were 
collected by centrifugation and resuspended in MSC medium before plating into 
a 10 cm2 tissue culture dish. Fresh amniotic fluid samples were collected under 
the approval of The Research Ethics Committee of University College London 
Hospital. After obtaining informed consent, human AFSCs were isolated from 
the amniotic fluid between 15 to 22 weeks of gestation (of a healthy pregnancy). 
Firstly, amniotic fluid was filtered with a 0.75 µm filter before centrifugation for 
pellet collection. The pellet was then resuspended in MSC medium (DMEM + 
10% FBS) and plated in a 10 cm2 tissue culture dish. When the first colony 
appeared, cells were detached by TrypLE (Invitrogen) and passaged into a new 
culture dish.  
 
RNA extraction and cDNA synthesis 
The cell pellet was collected with TrypLE and centrifuged before the total RNA 
was extracted using an RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. 1 ug of RNA was used as a template for cDNA 
synthesis using a High Capacity cDNA Reverse Transcription Kit (Thermo 
Scientific) according to the manufacturer’s instructions. The ‘5-day VPA’ RNA 
sample used in the Wnt array experiment was collected by a previous lab 
member. All other samples were collected by me. Since the protocol of VPA-
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induced AFSCs reprogramming was not reproducible in my hands, I did not 
collect any VPA-induced CiPSCs samples in this study.  
 
Array 
The human Wnt signalling pathway array plate (QIAGEN) and Human 
Epithelial-to-Mesenchymal Transition (EMT) array plate (QIAGEN) were used 
according to the manufacturer’s instructions. 5 ng of cDNA was used in each 
well. Target genes with more than a 2-fold difference compared to the control 
group were selected and presented graphically.  
 
Real-Time PCR 
cDNA was amplified using the ABI StepOne Sequence Detector system 
(Applied Biosystems) and SYBR Green (Wnt2, Wnt2B, Wnt3A, Wnt3, Wnt4, 
Wnt5A, Wnt8A, E-Cadherin, N-Cadherin, Snail1, Vimentin, Fibronectin, Oct4, 
Klf4, Sox2, and Nanog). Samples were normalized against the internal control 
(GAPDH). 10 ng of cDNA was used in each well.  
 
Flow Cytometry 
AFSCs were detached, dissociated into single cells using TrypLE (Invitrogen), 
and washed once with phosphate-buffered saline (PBS). The cell pellet was 
then resuspended in PBS containing 1% BSA. Samples were probed with Tra1-
60-PE (09-0009, Stemgent) antibody for 1 hour at 4C (1:200 dilution) followed 
by washes with PBS containing 1% BSA. Probed cells were resuspended in 
PBS and analyzed by flow cytometry (CyAn ADP, Beckman Coulter). 10,000 
cells from each sample were analyzed for the percentage of positive cells using 
the Flowjo v.10 software package (Treestar, Ashland, OR, USA). Negative 
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controls were treated with immunoglobulin G (IgG)-isotypes matching the 
isotype of the primary antibody. 
 
VPA-induced AFSCs reprogramming protocols 
AFSCs were plated in Matrigel-coated wells of a 6-well plate in MSC medium 
(DMEM + 10% FBS). Nutristem medium was then introduced 24 hours after 
plating and the medium was replaced daily for 5 days followed by 1 mM VPA 
treatment in Nutristem medium for an additional 5 days. Samples were 
collected after 10-days of treatment for analysis of pluripotency. For the test of 
different VPA concentrations, the same protocol was performed but with the 
appropriate VPA concentration (0.5 mM, 0.25 mM, 0.125 mM, and 0.1 mM). 
Samples were collected after 10 days of treatment. To determine the effects of 
the duration of culture in Nutristem, AFSCs were exposed to Nutristem for 
various time points (0 day, 1 day, 2 days, 3 days, 4 days, and 5 days) before 1 
mM VPA was introduced for 5 days. After the VPA treatment, cells were 
maintained in Nutristem until day 10 for sample collection. 
 
Statistical analysis 
Comparisons between groups were made using ANOVA. The p values <0.05 
were considered significant. The results were calculated using GraphPad-7 
(GraphPad, San Diego, CA, USA). Data were expressed as meanSEM 
(standard error of the mean). 
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Results 
Wnt signalling was downregulated in ESC conditions and upregulated in 
response to VPA treatment  
Wnt signalling has been reported to be involved in multiple cellular activities, 
including reprogramming. To investigate the role of Wnt signalling in CiPSC 
reprogramming, samples were collected from different time points of the VPA 
protocol (ESC-1 day, ESC-3 days, ESC-5 days, and VPA-5 days). Total RNA 
was then extracted for analysis of the expression of components of the Wnt 
family. The ‘VPA-5 days’ RNA sample was provided by a previous lab member. 
Our results indicate that Wnt signalling was downregulated in the early stages 
of culture in ESC conditions, and upregulated with VPA treatment compared to 
the control sample in MSC medium (Fig. 2.2A). Wnt family genes with more 
than a 2- fold change were selected. Within those selected genes, Wnt2, Wnt2B, 
Wnt3A, Wnt4, Wnt7A, Wnt8A and Wnt11 were consistently downregulated in 
the ESC condition and induced after VPA treatment (Fig. 2.2A). Wnt2 and 
Wnt2B were downregulated to the greatest extent. Moreover, Wnt activity 
signature genes showed a comparable pattern to the Wnt family, demonstrating 
that Wnt signalling was downregulated in the early stages and upregulated in 
response to VPA treatment (Fig. 2.2B). BOD1, CCND1, CCND2, CALM1, 
CHSY1, HSP A12A, MTFP1, LEF1, MTSS1, CCND2, MT1A, CYP4V2 and 
CXADR increased consistently in the ESC condition and decreased with VPA 
treatment. Wnt target genes showed similar results (Fig. 2.2C); CCND1, 
CCND2, JUN, BTRC, PPARD, WISP1, AXIN2 and MMP7 were downregulated 
in the ESC condition and induced by VPA stimulation. Downregulation of Wnt 
signalling in the early stages of CiPSC reprogramming followed by upregulation 
in the later stages shows a similar pattern to that which occurs during iPSC 
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reprogramming. Although the array results were consistent, only one sample 
was tested on each plate. Further validation was therefore performed to confirm 
these results.  
 
To validate the results from the array, RT-PCR was performed. Wnt2, Wnt2B, 
Wnt3A, Wnt4, Wnt8A and CCND1 were selected for validation. With the 
exception of Wnt2, which was consistently downregulated at the ESC stage, all 
other selected genes were upregulated in response to ESC conditions 
compared to control samples maintained in MSC medium (Fig. 2.2D). These 
results contradict those obtained in the array. Since only one sample was used 
for the array whereas three biological replicates were used for the RT-PCR we 
suggest that the results of the RT-PCR are more reliable than the results of the 
array. However, the differences in results are likely to be due to the lack of 
reproducibility of the CiPSC reprogramming protocol.   
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Figure 2.2 
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Figure 2.2 
Wnt family genes were downregulated in ESC conditions and 
upregulated upon VPA treatment.  
Array data to show (A) Wnt family genes with more than 2-fold difference 
compared to the control sample (B) Wnt activity signature genes with more than 
2-fold change compared to the control sample (C) Wnt downstream target 
genes with more than 2-fold change compared to the control group. Only one 
sample tested in the array experiment. (D) Wnt family genes selected from the 
array results were validated by RT-PCR with SYBR Green system. Three 
samples were examined in RT-PCR experiment. Data represent mean ± SEM 
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Markers of EMT increased in the early stages of the CiPSC 
reprogramming protocol  
Mesenchymal-to-epithelial transition (MET) is a key initial step of iPSC 
reprogramming. Here we investigated the role of MET in CiPSC reprogramming. 
RNA samples from AFSCs in the initial step i.e. ESC conditions, were collected 
at different time points (1 day, 3 days and 5 days). Due to the lack of 
reproducibility of the CiPSC reprogramming protocol, no VPA-reprogrammed 
AFSCs were available. An epithelial-to-mesenchymal transition (EMT) array 
was performed using 10 ug cDNA. Genes with more than 2-fold difference 
compared to the AFSCs grown in MSC medium were selected. Our results 
show that EMT marker genes increase in the initial step of CiPSC 
reprogramming (Fig. 2.3A), indicating that AFSCs were more mesenchymal-
like than epithelial-like in the initial step of the CiPSC reprogramming protocol. 
To confirm that EMT occurred in the initial step, key mesenchymal markers (N-
cadherin, Snail1, Vimentin, and Fibronectin) and an epithelial marker (E-
cadherin) were examined using RT-PCR. Loss of E-cadherin is considered to 
be the starting point of EMT and is followed by an increase in mesenchymal 
marker expression [197]. Downregulation of E-cadherin and upregulation of 
mesenchymal markers was shown at three different time points (Fig. 2.3B), thus 
indicating that, contrary to our original hypothesis, AFSCs undergo EMT when 
maintained in ESC conditions.  
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Figure 2.3 
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Figure 2.3 
Mesenchymal marker expression increases in the early stages of the 
CiPSC reprogramming protocol.  
(A) Genes with ≥ a 2-fold change were selected from the EMT array results at 
three different time points. One sample was tested in the array experiment. (B) 
Key epithelial (E-cadherin) and mesenchymal (N-cadherin, Snail1, Vimentin, 
and Fibronectin) markers were validated using RT-PCR. Three samples were 
tested in the RT-PCR experiment and data represent the mean ± SEM.  
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The lack of reproducibility of the CiPSC reprogramming protocol  
The CiPSC reprogramming protocol previously described by our lab [60] 
involves maintaining AFSCs in ESC conditions (Nutristem medium on Matrigel-
coated plates) for 5 days followed by 1 mM VPA treatment for an additional 5 
days. The pluripotency marker Tra1-60 was selected as an indicator of 
successful reprogramming and was assessed by flow cytometry. Following 
exposure of the cells to the original protocol, Tra1-60 expression was not 
detected (Fig. 2.4A). This experiment was repeated with three different samples 
and none of them showed expression of Tra1-60. Ntera-2, an embryonic 
carcinoma cell line, was used as a positive control whereas fibroblasts were 
used as a negative control.  
 
Several attempts were made to address the lack of reproducibility of VPA 
reprogramming protocol. Since stem cells are very sensitive to their culture 
environment and long-term culture leads to a decrease of the levels of 
‘stemness’, we isolated AFSCs from fresh amniotic fluid samples to determine 
whether the lack of reproducibility of the protocol was due to freeze-thawing of 
the AFSCs. Fresh AFSCs were treated with the original CiPSC reprogramming 
protocol at passage 5. After 5 days’ VPA stimulation, cells were collected and 
examined for Tra1-60 expression by flow cytometry. This experiment showed 
similar results to those obtained using the AFSCs samples collected by the 
previous lab member in that the absence of a Tra1-60-positive population was 
observed (Fig. 2.4B). These experiments were performed using three fresh 
AFSCs samples and in all cases the mean percentage of the Tra1-60-positive 
population was indistinguishable to that of the control group. Ntera-2 and 
fibroblast were used as positive and negative controls respectively.  
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Figure 2.4 
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Figure 2.4 
The lack of reproducibility of the CiPSC reprogramming protocol. 
(A) AFSCs samples collected by a previous lab member and (B) Freshly-
isolated AFSCs were exposed to the original CiPSC reprogramming protocol. 
Cells were then collected for the examination of Tra1-60 expression using flow 
cytometry. Three samples were examined in this experiment. Fibroblast and 
Ntera-2 were used as negative and positive controls respectively. Percentage 
of the Tra1-60 positive population was shown as mean ± SEM.  
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Altering the VPA concentration does not improve the reproducibility of 
the CiPSC reprogramming protocol 
Since the source of the AFSCs was not the cause of the lack of reproducibility 
of the protocol, different VPA concentrations were tested. 0.5 mM, 0.25 mM, 
0.125 mM, 0.1 mM VPA were used to treat the cells instead of the 1 mM 
concentration used in the original protocol during the VPA induction stage. After 
the 10 day protocol, cells were collected for Tra1-60 examination by flow 
cytometry. The results demonstrated that levels of expression of Tra1-60 were 
similar to the levels of expression in the control group maintained in MSC 
medium (Fig. 2.5A). Three different samples were tested and the mean of the 
Tra1-60 positive population was comparable to control group in all three.  
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Figure 2.5 
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Figure 2.5 
Decreasing the concentration of VPA does not restore the reproducibility 
of the CiPSC reprogramming protocol. 
Different concentrations of VPA (0.5 mM, 0.25 mM, 0.125 mM, 0.1 mM ) were 
tested in an attempt restore the reproducibility of the original CiPSC 
reprogramming protocol. Cells were then collected for Tra1-60 expression 
analysis by flow cytometry. Three samples were examined in this experiment. 
Ntera-2 was used as a positive control. Percentage of the Tra1-60 positive 
population was shown as mean ± SEM.  
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Shortening the initial stage of the CiPSC reprogramming protocol led to 
Tra1-60 expression but not the expression of other pluripotent markers. 
Different VPA concentrations had no effect on Tra1-60 expression in AFSCs. 
Therefore, the duration of the initial stage of the CiPSC reprogramming protocol 
(in ESC conditions) was then varied to determine whether this would affect 
Tra1-60 expression. The original protocol described the maintenance of AFSCs 
in ESC conditions for 5 days prior to VPA stimulation. Here we tested 0, 1, 2, 3, 
4 and 5 days in ESC conditions prior to VPA stimulation. Results showed that 
when cells were exposed to ESC conditions from 0 day to 3 days followed by 
1mM VPA treatment for 5 days, the cell size decreases (Fig. 2.6A). Amongst 
these four conditions (0 day to 3 days), 2 days in ESC conditions showed the 
greatest cell-size shift (Fig. 2.6A). Moreover, the smaller size population 
demonstrated increased expression of Tra1-60, which was not observed in the 
larger cell population (Fig. 2.6B). Conversely, a shift in cell size and increase in 
Tra1-60 expression were not detected in the 4 and 5 day culture conditions (Fig. 
2.6A). It has been reported that, during cellular reprogramming, a MET occurs 
leading to a smaller cell size compared to the original cell type [193]. Our results 
demonstrate this effect. As a result of these preliminary results, exposure times 
of 1 day and 2 days in ESC conditions followed by 1mM VPA treatment were 
chosen for further examination of pluripotency.  
 
In order to validate the pluripotency of AFSCs stimulated by the modified CiPSC 
reprogramming protocol (1 and 2 days in ESC conditions prior to VPA 
treatment), RT-PCR was performed to assess the expression of various 
pluripotent markers, including Oct4, Klf4, Sox2, and Nanog. However, these 
pluripotent markers were expressed at comparable levels to the control 
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samples (Fig. 2.6C). These results were contrary to our previous published 
results, which showed that AFSCs, reprogrammed using the CiPSC 
reprogramming VPA protocol, exhibited more than 100-fold increases in 
expression of pluripotency-associated genes compared to the control group [60, 
61].  
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Figure 2.6 
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Figure 2.6 
AFSCs stimulated with the modified protocol increased Tra1-60 
expression but not the expression of other pluripotent markers.   
(A) Different days of incubation (0, 1, 2, 3, 4, and 5) in ESC conditions were 
tested followed by 1 mM VPA treatment for 5 days. Cells were then collected 
for flow cytometry analysis of Tra1-60 expression. (B) With different incubation 
days, two populations with different size (large and small) were gated for further 
Tra1-60 expression analysis. (C) To determine whether reprogramming was 
successful, pluripotency-related gene (Oct-4, Klf4, Sox2, and Nanog) 
expression was assessed using RT-PCR. Ntera-2 was used as a positive 
control. Percentage of the Tra1-60 positive population and RT-PCR results 
were shown as mean ± SEM. Three samples were tested for all experiments. 
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The smaller population was composed of dead cells. 
AFSCs reprogrammed with the modified protocol with 1 and 2 days in ESC 
conditions prior to VPA stimulation showed an increase in Tra1-60 expression. 
However, after VPA stimulation, AFSCs cannot be maintained in culture. Very 
few cells attached after passaging and the attached cells did not proliferate 
(Fig.2.7A). To determine the viability of the cells, flow cytometry with PI staining 
was performed. The results showed that the smaller cell population was positive 
for PI, indicating that they were dead (Fig. 2.7B). Whereas the larger cell 
population showed less PI positivity (Fig. 2.7B). These results demonstrate that 
the majority of the cells were died in response to exposure to the modified 
protocol, indicating that the Tra1-60 positive population of smaller cells is likely 
to be false positive due to cell death. 
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Figure 2.7 
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Figure 2.7 
Severe cell death was observed in response to the modified CiPSC 
reprogramming protocol.  
(A) Representative cell morphology in response to the modified CiPSC 
reprogramming protocol. (B) To confirm the cellular viability after the modified 
protocol, flow cytometry with PI staining was performed. Large and small cell 
populations were gated for analysis. Three samples were used for all 
experiments. 
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Discussion 
Wnt signalling plays multiple roles in controlling cell fate such as maintaining 
stem cell potency and differentiation, carcinogenesis, and cellular migration. In 
addition, Wnt signalling contributes to reprogramming of somatic cells to 
functional pluripotency. Wnt activity varies throughout the different stages of 
reprogramming. For example, in the early stages, inhibition of Wnt signalling 
initiates the reprogramming process, whereas activation of Wnt is required in 
the later stages of reprogramming to promote the stabilisation of the pluripotent 
state. The microarray results of the different stages of CiPSC reprogramming 
demonstrated similar patterns of Wnt signalling to those that occur during iPSC 
reprogramming whereby Wnt signalling was downregulated in the early stages 
then upregulated following VPA treatment. However, only one sample was used 
for each time point. Real-time PCR, in triplicate, showed opposite results to the 
array. This discrepancy suggests that the results obtained from the RT-PCR are 
more reliable than those obtained in the array. For example, a loading error may 
have occurred in the array procedure leading to inaccurate results.  
 
In addition to the regulation of signalling pathway activity during reprogramming, 
cellular morphology changes from mesenchymal to epithelial (MET) are 
essential for successful reprogramming. However, our results showed that 
genes involved in the opposite transition, EMT, were upregulated in the initial 
step of the CiPSC reprogramming protocol. The array results were confirmed 
by the RT-PCR which demonstrated the upregulation of key mesenchymal 
markers and downregulation of epithelial markers throughout the CiPSC 
reprogramming protocol. A positive control was not available due to the lack of 
reproducibility of the CiPSC reprogramming protocol. Several approaches were 
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taken to troubleshoot the CiPSC reprogramming protocol, but these were all 
unsuccessful. Therefore we cannot draw conclusions regarding the role of Wnt 
signalling and MET in our CiPSC reprogramming protocol. We did not observe 
MET in the initial step of our CiPSC reprogramming protocol, but it could be the 
case that MET occurs at a later stage of CiPSC reprogramming than iPSC 
reprogramming, or that it does not occur at all. Similarly, we cannot draw 
conclusions about the role of Wnt signalling in the process from the data 
presented here.  
       
The original CiPSC reprogramming protocol involved maintaining AFSCs in 
ESC conditions (Nutristem medium on Matrigel-coated plates) for 5 days 
followed by 1 mM VPA treatment for an additional 5 days. We show here that 
this did not induce the expression of Tra1-60 as was previously demonstrated 
[60]. Variations in VPA concentration and the duration of exposure to ESC 
conditions in the initial step did not affect the expression of Tra1-60, which 
remained at basal levels in all conditions tested. Moreover, cell death was 
observed when the number of days of exposure to ESC conditions was reduced. 
Other groups have reported similar problems with reprogramming in the 
presence of Nutristem medium. For example, an open letter from Prof. Rossi 
from the Program in Cellular and Molecular Medicine at Harvard Stem Cell 
Institute reported a lot-to-lot variation of Nutristem which led to the failure of a 
micro RNA reprogramming protocol. To overcome this, the manufacturer 
(Stemgent) have suggested replacing Nutristem with another reprogramming 
medium (Pluriton) for their micro RNA protocol. However, other ESC media, 
including mTesr, Pluriton and Essential 8, have been used in the CiPSC 
reprogramming protocol by other lab members with limited success. Although 
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Dr. Dafni Moschidou, who established the original protocol, was able to 
reprogram AFSCs using the original protocol, this has not been replicated by 
other past and present group members.  
 
Conditions for cryopreservation and maintenance of AFSCs in vitro have not 
yet been standardized. Several different media can be used to preserve the 
features of AFSCs in vitro, the most common being Dulbecco’s modified Eagle’s 
medium (DMEM) with different supplements. However, these culture conditions 
have been shown to lead to a decrease in the ability of AFSCs to proliferate 
and differentiate, at least at later passage [198]. Moreover, AFSCs are usually 
cryopreserved in their maintenance medium, which may affect the cell 
characteristics during long term preservation. The AFSCs samples collected by 
previous lab members have been cryopreserved and maintained in vitro for a 
long period, and this may be a contributing factor in the lack of reproducibility 
of the protocol. To confirm that the cryopreservation method or passage number 
of the AFSCs were not causing the lack of reproducibility of the CiPSC 
reprogramming protocol, freshly isolated, low-passage AFSCs were also 
exposed to the protocol. However, the protocol was not reproducible even with 
freshly-isolated AFSCs. However this may be due to the observation that the 
morphology of AFSCs obtained from the new amniotic fluid samples (round-
shape) is different from that of the old samples (spindle-shape). The difference 
between round-shape and spindle-shaped AFSCs populations are currently 
under investigation by other members of the lab.  
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Conclusion 
In this chapter, we explore the possible mechanisms involved in CiPSC 
reprogramming of AFSCs, with a focus on the role of Wnt signalling and MET. 
However, since the CiPSC reprogramming protocol is yet to be reproduced, we 
are unable to draw conclusions from the work presented here. We are still 
unsure as to which factors have led to the failure of the CiPSC reprogramming 
protocol since its initial discovery. Nutristem is one potential candidate which, if 
responsible, would affect the array results regarding the roles of Wnt signalling 
and MET. In conclusion, further studies are necessary to restore the 
functionality of the CiPSC reprogramming protocol we previously described.    
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TGFβ-induced osteogenic potential of 
AFSCs via CD73-generated adenosine 
production 
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Introduction 
Amniotic fluid is a promising source of primitive stem cells, known as amniotic 
fluid stem cells (AFSCs). Like mesenchymal stem cells (MSCs), AFSCs are 
capable of mesenchymal tri-lineage differentiation (osteogenesis, adipogenesis, 
and chondrogenesis) [103, 151]. Moreover, since AFSCs represent an 
intermediate stage between embryonic stem cells (ESCs) and MSCs, AFSCs 
possess greater abilities to self-renew and differentiate than MSCs but not to 
the extent that ESCs do [103]. For example, besides mesenchymal tri-lineage 
differentiation potential, AFSCs can give rise to cell types from the other two 
germ layers, ectoderm and endoderm [103, 146, 199, 200]. Furthermore, 
although AFSCs have previously been shown to express markers of 
pluripotency, such as SSEA3 and SSEA4 [60], there are no ethical issues 
associated with their use as there are with ESCs. Despite this, AFSCs lack the 
capacity to form teratomas and contribute to chimeric mice, thus indicating that 
AFSCs are not pluripotent [103]. Therefore, AFSCs may represent a safer stem 
cell source for clinical applications. 
  
MSCs have been reported to possess numerous clinical benefits, however, they 
have limited proliferation capacity in vitro, making generating the numbers of 
cells required by clinics challenging [132]. AFSCs, on the other hand, 
demonstrate a greater proliferation capacity due to their long telomeres and 
may therefore be a better candidate for clinical applications than MSCs [60]. 
Moreover, AFSCs have been reported to have greater multipotency than MSCs, 
being able to differentiate into cardiomyogenic, neurogenic, hepatic and various 
other lineages [103, 120, 199]. However, compared to standard MSCs from 
bone marrow, AFSCs are relatively new sources of stem cells. Similarly, bone 
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marrow-derived MSCs have been well studied, whereas AFSCs are still not 
completely understood. For example, culture conditions for maintaining AFSCs 
in vitro haven’t yet been standardized. In particular, AFSCs are highly 
heterogeneous meaning that different conditions may support the growth of 
different populations from amniotic fluid samples, which may then result in 
variation between studies.       
 
From the perspective of embryonic development, AFSCs represent an 
intermediate stage between ESCs and MSCs. Numerous different culture 
conditions have been established to isolate and maintain AFSCs in vitro [120]. 
Dulbecco’s modified Eagle’s medium (DMEM) with different supplements is one 
of the most commonly used conditions. For instance, AFSCs maintained in 
DMEM supplied with 10% or 20% fetal bovine serum (FBS) with or without basic 
fibroblast growth factor (bFGF) demonstrated MSC characteristics, including tri-
lineage differentiation potential and the expression of MSC markers [60, 200]. 
Similar results can be obtained with alternative culture conditions, such as 
Alpha Modified Eagle’s Medium (MEM) containing FBS or Chang medium 
[103]. However, these culture conditions are suitable only for maintaining MSCs, 
not ESCs, features. Since AFSCs are more primitive than MSCs and 
phenotypically closer to ESCs, the potential to grow AFSCs in ESC conditions, 
therefore maintaining their primitive features, will be examined in this study. We 
have previously demonstrated that AFSCs maintained in ESC conditions 
shared 82% transcriptome similarity to ESCs [60]. However, we still lack 
understanding of the effect of ESC culture conditions on cellular phenotype and 
function. 
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Aims 
In this study, freshly-isolated AFSCs will be maintained either in ESC (Nutristem 
+ Matrigel) or MSC (DMEM + 10%FBS) conditions and their MSCs vs. ESCs 
characteristics will be compared, including marker expression and 
differentiation ability. We hypothesize that ESC conditions will have an 
enhanced ability to preserve the primitive features of AFSCs.  
 
Materials and methods 
Ethics statement.  
The healthy donors who provided mid-trimester amniotic fluid in this study gave 
informed consent in writing in accordance with the Declaration of Helsinski. The 
ethical approval given by the joint Research Ethics Committee of University 
College London (UCL) and UCL Hospital (Ethics of Human Research) 
approved the collection of amniotic fluid stem cells (REC 08/H0714/87), in 
compliance with UK national guidelines (Review of the Guidance on the 
Research Use of Fetuses and Fetal Material (1989), also known as the 
Polkinghorne Guidelines. London: Her Majesty’s Stationery Office, 
1989:Cm762) for the collection of human fetal tissue for research. 
 
Isolation and Culture of AFSCs 
The Research Ethics Committee of University College London Hospital 
approved the collection of amniotic fluid. After obtaining informed consent, 
human amniotic fluid, between 15 to 22 weeks of gestation (of a healthy 
pregnancy), was collected from the donors. Fresh fluid was filtered with 0.75 
µm filter before being divided into two tubes. The amniotic fluid was then 
pelleted by centrifugation and resuspended as a single cell suspension either 
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in MSC medium, Dulbecco’s Modified Eagle’s Medium (DMEM-HG) (Invitrogen) 
supplemented with 10% FBS (Biosera), 2 mM L-Glutamine, 50 IU/ml penicillin 
and 50 mg/ml streptomycin (Gibco-BRL); or in ESC medium, Nutristem XF/FF 
(Stemgent). A tissue culture dish was used for the MSC condition and another 
tissue culture dish coated with Matrigel (BD) was used for the ESC condition. 
When the first colony appeared, clones of cells with a round-shape (RS) 
morphology were detached, pooled and resuspended in either the MSC or ESC 
conditions and re-plated. Alternatively, the cells were cultured in either MSC or 
ESC conditions over the first 5 passages, and were subsequently switched to 
ESC or MSC conditions, respectively (MSC-ESC and ESC-MSC conditions). 
The cells were cultured for an additional 5 passages before further examination. 
All cells were analyzed at passage 10. The cells were maintained at 37°C in a 
5% CO2 incubator.  
 
Alkaline phosphatase activity staining 
The staining solution was prepared according to the manufacturer’s instructions. 
Staining solution contained 0.1 M Tris-HCl, 0.1 M NaCl, 0.05 M MgCl2, 0.5% 
Tween 20, and 2% NBT/BCIP stock solution (Roche). AFSCs in MSC 
conditions were used to set the incubation time for the other three conditions. 
All conditions were then incubated for the same amount of time as the MSC 
condition. The percentage of positive cells was analyzed using ImageJ software.  
 
Flow Cytometry 
Cells were detached, dissociated into single cells using TrypLE (ThermoFisher) 
and washed with PBS. The cell pellet was then resuspended in phosphate-
buffered saline (PBS) containing 1% BSA. For cell surface marker staining, 
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samples were probed with the following conjugated primary antibodies: CD73-
PE (130-095-182, Miltenyi), CD105-FITC (130-094-926, Miltenyi), CD90-PE-
VIO770 (130-099-295, Miltenyi), CD45-PE (130-098-141, Miltenyi), CD34-APC 
(130-098-139, Miltenyi), CD24-APC (130-098-861, Miltenyi), CD117-PE (130-
091-734, Miltenyi), SSEA4-PE (FAB1435P, R&D), SSEA1-PE (FAB2155P, 
R&D), and TRA1-60-PE (09-0009, Stemgent), for 1 hour at 4C followed by 
washes with PBS + 1% BSA. For intracellular staining, Oct4-A (130-105-606, 
Miltenyi) and Oct4-AB (IC1759P, R&D), the cells were washed once in washing 
buffer and fixed for 10 min in 0.01% paraformaldehyde (PFA) followed by two 
washes with washing buffer. The cell pellet was then resuspended in 
permeabilization buffer (PBS + 1% Triton) for 10 min and washed once with 
washing buffer. Samples were then stained as described for surface markers 
above. The stained cells were resuspended in PBS and analyzed by flow 
cytometry (CyAn ADP, Beckman Coulter). 10,000 cells from each sample were 
collected and data were analyzed for the percentage of positive cells, cell size 
with forward scatter (FSC), and mean fluorescence intensity (MFI) using the 
Flowjo v.10 software package (Treestar, Ashland, OR, USA). Negative controls 
were immunoglobulin G (IgG) primary antibody-specific isotypes. 
 
RNA extraction and cDNA synthesis 
The cell pellet was collected with TrypLE followed by centrifugation and the total 
RNA was extracted using RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. 1 ug of RNA was used as templates for cDNA 
synthesis using High Capacity cDNA Reverse Transcription Kits (Thermo 
Scientific) according to the manufacturer’s instructions. 
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Real-Time PCR 
The generated cDNA was amplified using the ABI StepOne Sequence Detector 
system (Applied Biosystems) with SYBR Green Assay (Collagen I, Osteopontin 
(OP), Osteocalcin (OC), Rux2, alpha Fetoprotein (AFP), CD31, and Beta-III 
tubulin). Samples were normalized against the internal control (GAPDH). 10 ng 
of cDNA was used in each well.  
 
Growth kinetics 
The growth rate of AFSCs was estimated by plating 20,000 cells per well in a 
12-well tissue culture plate in triplicate (3 samples). Every 24 hours, the cells 
were detached and counted using a hemocytometer in trypan blue to exclude 
dead cells. Six time points were collected for growth rate analysis. To compare 
the cumulative population doublings of the cells cultured in different conditions, 
the cells were plated in triplicate at a concentration of 104 cells per cm2 in 10-
cm2 dishes and successively sub-cultured at the same density when sub-
confluent. This re-plating procedure was serially repeated over 6 passages, and 
the cumulative population doublings were determined by counting the number 
of adherent cells at the start and end of each passage.  
 
MSC Tri-lineage differentiation 
Cells from different culture conditions were detached using TrypLE and counted. 
40,000 cells were then seeded per well in 24-well plates. When the cells 
reached 90-100% confluence, the medium was replaced with differentiation 
medium. Osteogenic medium (DMEM supplemented with 10% FBS, 2 mM L-
Glutamine, 50 IU/ml penicillin, 50 mg/ml streptomycin, 10-8M dexamethasone, 
10-3M ascorbic acid, and 10mM beta-glycerophophate (all Sigma-Aldrich)) was 
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freshly prepared before use. Adipogenic medium (ThermoFisher) and 
chondrogenic medium (ThermoFisher) were prepared according to the 
manufacturer’s instructions. All differentiation media were replaced twice a 
week for 21 days incubation. To detect differentiation abilities from different 
samples, RNA samples were collected as previously described. Real time PCR 
was then performed for osteogenic, adipogenic, and chondrogenic markers. 
 
Alizarin Red  
To detect mineralized nodules of osteogenesis, cell culture plates were fixed in 
4% paraformaldehyde for 10 min followed by being washed in PBS and stained 
for 1 hour with 1% solution of Alizarin Red. Plates were then washed in water 
and left to air dry. The staining intensity relative to the mineralization condition 
was then quantified using Image J software. 
 
CD73, Adenosine, TGF-, and TGF- inhibitor treatment 
The CD73 inhibitor, adenosine 5’-(,-methylene) diphosphate (200 µM, 
M3763 Sigma-Aldrich), and adenosine (10 µM, A9251 Sigma-Aldrich) were 
added daily into the osteogenic differentiation medium during the 3 weeks of 
differentiation. To observe the effect of TGF- in CD73 expression and 
osteogenesis, TGF- (5 ng/ml, T7039 Sigma Aldrich) and TGF- inhibitor (1 µM, 
S4371 Sigma Aldrich) were added and daily to the culture media 10 days before 
performing osteogenic differentiation. 
  
Immunofluorescent staining 
For immunostaining, 10,000 cells were seeded on coverslips. 24 hours later, 
4% paraformaldehyde was incubated for 10 min for fixation, followed by 
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permeabilization with 0.5% Triton-X100 in PBS for 15 min. Samples were then 
washed with PBS and incubated with blocking buffer (PBS + 5% normal goat 
serum) for an hour. Primary antibody (Smad2/3, Cell Signaling Technology), at 
its optimal dilution (1:200) in blocking buffer, was then added and the cells were 
incubated overnight at 4C. Samples were then washed with PBS and 
incubated with secondary antibody (A11008, ThermoFisher) for 1 hour at room 
temperature. DAPI was used for nuclear staining after washing with PBS. 
Images were obtained using a confocal microscope (Zeiss LSM7100).  
 
Formation of embryoid body  
The hanging drop method was performed for the embryoid body (EB) formation 
test. 25 drops (containing 10,000 cells in 20 µl Nutristem medium) were seeded 
on the lid of a petri dish. The drops were then incubated for 10 days before 
being collected in Nutristem and transferred to a petri dish in DMEM+20% FBS 
for an additional 5 day incubation. EBs were then collected for RNA extraction 
and real time PCR analysis of markers of the three germ layers (AFP, CD31, 
and –III Tubulin).  
 
Endoderm differentiation 
For endoderm differentiation, AFSCs were seeded at 40,000 cells per well in 
gelatin-coated 24-well plates in the appropriate medium. 24 hours after plating, 
the media were changed to total RPMI (containing 1% NEAA, 1% penicillin and 
streptomycin, 10% B27 plus insulin, 100 ng/ml of activin, 80 ng/ml of FGF2, 10 
ng/ml of BMP4, 10 µM of LY294002, and 3 µM of CHIR99021), for 24 hours 
incubation. The next day, the culture media was changed to total RPMI without 
CHIR99021 for another 24 hours incubation. After 24 hours, the media was 
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changed to total RPMI without NEAA, B27, BMP4, LY294002 or CHIR99021 for 
another day incubation. From day 4, cells were maintained in RPMI with 1% 
penicillin and streptomycin and 50 ng/ml of activin alone. Samples were 
collected at day 7 for further analysis.  
    
Ectoderm differentiation 
For ectoderm differentiation, AFSCs from different conditions were seeded at 
40,000 cells per well in 24-well plates in the appropriate culture media: DMEM 
or Nutristem. After 24 hours’ incubation, each well was washed once with PBS 
and the medium changed to ectoderm differentiation medium (DMEM-Ham F12 
medium with glutamine supplemented with N2 (Gibco), B27 (Gibco), P/S, 
20ng/ml EGF and 20 ng/ml bFGF). Cells were incubated with differentiation 
medium for 7 days before samples were collected for immunostaining and RNA 
extraction. 
 
Statistical analysis 
Comparisons between groups were made using ANOVA. The p values <0.05 
were considered significant. The results were calculated using GraphPad-7 
(GraphPad, San Diego, CA, USA). Data were expressed as meanSEM 
(standard error of the mean). 
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Results 
Stem cell markers were preserved in AFSCs maintained in both MSC and 
ESC culture conditions 
To investigate the effect of different culture conditions on AFSCs, second 
trimester amniotic fluid samples were collected and split into two. Half were 
maintained in MSC conditions (DMEM + 10% FBS) and the other half in ESC 
conditions (Nutristem + Matrigel). Cells were analyzed at passage 5. Cell 
morphology and size were comparable between the two conditions (Fig. 3.1A). 
However, alkaline phosphatase (AP), an early fetal development marker, 
showed a significant increase in ESC conditions (Fig. 3.1A). In addition to being 
an early fetal development marker, AP has been reported to play a part in cell 
proliferation and osteogenesis as well. Altered AP activity may therefore affect 
these cellular functions.  
 
In order to confirm that AFSCs maintained in both conditions met the criteria 
used to define MSCs, the expression of CD105, CD73, CD90, CD117, CD45, 
and CD34 were examined by flow cytometry. CD73 and CD90 were well 
preserved in both conditions (Fig. 3.1B), whereas CD105 was preserved better 
in ESC conditions (Fig. 3.1B). CD117, an AFSC marker, was absent in both 
conditions (Fig. 3.1B). This is likely to be because CD117 has been shown to 
be expressed only in early passage AFSCs and decreases over time in vitro 
[201]. CD45 was expressed at low levels in both conditions and CD34 was 
negative in both MSC and ESC conditions, which ruled out potential 
contamination from blood cells (Fig. 3.1B). The expression of ESC markers, 
such as Oct4A, Oct4AB, SSEA1, SSEA4, Tra1-60 and CD24, was then 
investigated by flow cytometry. Oct4A, a pluripotency-associated marker, was 
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not detected in either condition (Fig. 3.1C); whereas Oct4AB, a non-
pluripotency-associated marker, was positive in both conditions (Fig. 3.1C). 
SSEA1 was expressed at low levels in both conditions and Tra1-60 was 
undetected whereas SSEA4 and CD24 were both positive in MSC and ESC 
conditions (Fig. 3.1C). Our results indicate that the expression of stem cell 
markers in AFSCs is maintained in both MSC and ESC conditions, with the 
expression of some of these markers being enhanced by ESC culture 
conditions.  
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Figure 3.1 
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Figure 3.1 
Characterization of AFSCs cultivated in MSC and ESC conditions. 
Fresh AFSCs samples were collected and divided into two conditions, MSC and 
ESC. (A) Representative cell morphology was shown at passage 5 in both 
conditions. Cell size was analyzed by forward scatter (FSC) from flow cytometry. 
Alkaline phosphatase was stained and the positive area was analyzed by 
ImageJ software. Data represent mean ± SEM. AFSCs maintained in both 
conditions were then examined for the expression of (B) MSC markers (CD105, 
CD73, CD90, CD117, CD45, and CD34) and (C) pluripotent markers (Oct4A, 
Oct4AB, SSEA1, SSEA4, Tra1-60 and CD24) at passage 5 by flow cytometry. 
10,000 cells were collected for measurement. Three samples were examined 
in all the experiments. *=P<0.05. 
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AFSCs’ features can be manipulated by culture environment  
To further our understanding of the effect of culture conditions on cellular 
features, AFSCs were switched either from MSC medium to ESC medium 
(MSC-ESC) or from ESC medium to MSC medium (ESC-MSC). AFSCs were 
then maintained in these conditions for 5 more passages before analysis. Cell 
morphology and size were comparable between the four conditions (MSC, 
MSC-ESC, ESC and ESC-MSC) (Fig. 3.2A). However, AP activity was 
significantly affected by the culture conditions; AFSCs maintained in ESC 
conditions demonstrated greater AP activity compared to those maintained in 
MSC conditions. In addition, AP activity increased significantly in the MSC-ESC 
condition compared to MSC culture conditions alone, whereas AP activity in the 
ESC-MSC condition decreased dramatically compared to ESC culture 
conditions alone (Fig. 3.2A). AFSCs cultured in both MSC-ESC conditions and 
ESC-MSC conditions maintained the expression of the MSC markers CD105, 
CD73, and CD90 and lacked expression of CD117. CD45 was expressed at low 
levels in both MSC-ESC and ESC-MSC culture conditions and CD34 was 
negative in all conditions. (Fig. 3.2B). Both MSC-ESC and ESC-MSC conditions 
showed similar expression levels of ESC markers as their original conditions, 
with a lack of expression of Oct4A and Tra1-60, low level expression of SSEA1 
and positive expression of Oct4AB, SSEA4, and CD24 (Fig. 3.2C). 
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Figure 3.2 
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Figure 3.2 
Characterization of the effects of switching culture conditions on AFSCs.  
To further investigate the effect of culture conditions on cellular features, AFSCs 
were switched from MSC to ESC or ESC to MSC conditions at passage 5. The 
cells were analyzed at passage 10. (A) Representative phase contrast images 
of AFSCs. The relative size of AFSCs cultured in different conditions was 
analyzed using the mean value of forward scatter (FSC) from 3 samples. The 
positive stained area of alkaline phosphatase was measured by Image J. Data 
represent mean ± SEM. (B) Expression of MSC markers (CD105, CD73, CD90, 
CD117, CD45, and CD34) were examined by flow cytometry. (C) Expression of 
ESC markers (Oct4A, Oct4AB, SSEA1, SSEA4, Tra1-60, and CD24) were 
assessed by flow cytometry. Three samples were examined in all the 
experiments. *=P<0.05. 
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Higher CD73 and SSEA4 expression were found in AFSCs maintained in 
ESC conditions 
The percentage of the AFSCs population positive for CD73, CD90, CD105, 
SSEA4, CD24, and Oct4AB was measured using Flowjo software. All markers 
demonstrated comparable expression levels across the four different culture 
conditions (Fig. 3.3A). However, the mean fluorescence intensity (MFI) for 
CD73, CD90, SSEA4, and CD24 increased in both ESC conditions (ESC and 
MSC-ESC) whereas CD105 and Oct4-AB were indistinguishable among 
different groups (Fig. 3.3B). Additionally, the MFI of CD73 increased 
significantly in both ESC conditions compared to MSC conditions (Fig. 3.3B). 
SSEA4 demonstrated a similar pattern as CD73 but only showed a significant 
increase in the MSC-ESC group compared to the MSC condition (Fig. 3.3B).  
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Figure 3.3 
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Figure 3.3 
Greater levels of expression of CD73 and SSEA4 were observed in ESC 
conditions 
(A) The percentage of positive cells for each marker (obtained using flow 
cytometry) were analyzed by Flowjo software. (B) The mean fluorescence 
intensity (MFI) was also analyzed with Flowjo software to show the different 
expression level of markers across different conditions. Three samples were 
examined in all the experiments for each condition. Data represent mean value 
± SEM. *=P<0.05. 
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AFSCs maintained in ESC conditions exhibited increased growth kinetics 
compared to MSC conditions 
In addition to the expression of stem cell markers, the effect of culture 
environment on growth kinetics was examined. An increased proliferation rate 
was observed in AFSCs expanded in ESC conditions (ESC or MSC-ESC) than 
in MSC conditions (MSC or ESC-MSC), as evidenced by the higher cumulative 
population doubling (CPD) value (7.60.8 and 7.50.8 for MSC conditions vs. 
12.61.2 and 13.21.3 for ESC conditions, p<0.001) over 16 days (Fig. 3.4A). 
These results indicate that maintaining AFSCs in ESC conditions favours their 
expansion and survival.  
 
Improved osteogenesis was observed in AFSCs maintained in ESC 
conditions compared to those maintained in MSC conditions 
Tri-lineage differentiation capacity is a defining characteristic of MSCs. To gain 
further understanding of the effect of culture conditions on differentiation ability, 
tri-lineage differentiation was performed using AFSCs maintained in the 
different media conditions. After 21 days of stimulation, cells were collected for 
RT-PCR analysis of the expression of lineage-specific markers. Adipogenic and 
chondrogenic differentiation potential were comparable across the four 
conditions (Fig. 3.4B). However, improved osteogenic differentiation potential 
was observed in AFSCs maintained in ESC conditions (ESC and MSC-ESC), 
as demonstrated by the significantly higher Col1A1 and Col1A2 expression in 
cells maintained in these conditions (Fig. 3.4B). In addition, the levels of calcium 
production from differentiated osteocytes, as demonstrated by Alizarin Red 
staining, increased significantly in both ESC (ESC and MSC-ESC) conditions 
compared to MSC (MSC and ESC-MSC) conditions (Fig. 3.4B).   
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Figure 3.4 
AFSCs sustained in ESC conditions showed improved osteogenesis and 
growth kinetics.  
(A) Cumulative population doubling was calculated over 6 passages and 
cumulative cell numbers were calculated over 6 days. (B) Tri-lineage 
differentiation was performed. After 21 days induction, RNA samples were 
analysed for the expression of PPARr and FAB for adipogenesis, Sox9 and 
Rux2 for chondrogenesis, and Cola1a and Col1a2 for osteogenesis. Alizarin 
Red staining was used to stain calcium deposition from osteocytes. The positive 
Alizarin Red area was measured by ImageJ. Three samples were examined in 
all the experiments. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. 
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Upregulation of CD73 in ESC conditions enhanced osteogenic 
differentiation 
AFSCs maintained in ESC conditions exhibited better osteogenic differentiation 
potential and higher CD73 expression. CD73 has previously been shown to 
regulate osteogenic differentiation. For example, osteoblasts from CD73-
deficient mice exhibit decreased osteogenic differentiation potential [202]. 
Moreover, adenosine (converted from AMP) is a known downstream product of 
CD73 and also plays a role in osteogenesis [202, 203]. To better understand 
the role of CD73 in enhancing osteogenic differentiation in ESC conditions, 
either a CD73 inhibitor (CD73i) or adenosine were introduced to the 
differentiation medium. In the presence of CD73i, osteogenesis was reduced in 
all conditions compared to the control differentiation medium without any 
supplement as demonstrated by downregulation of the osteocyte markers Col1, 
OP, OC, and Runx2  (Fig. 3.5A) and decreases in Alizarin red staining (Fig. 
3.5B). Conversely, differentiation medium supplemented with adenosine 
enhanced osteogenic differentiation, causing an upregulation of osteogenic 
markers in all conditions (Fig. 3.5A) and increased Alizarin Red staining (Fig. 
3.5B). Our results indicate that upregulation of CD73/adenosine is involved in 
enhancing the osteogenic differentiation of AFSCs sustained in ESC conditions.  
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Figure 3.5 
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Figure 3.5 
Increased expression of CD73 enhanced osteogenesis of AFSCs 
maintained in ESC conditions. 
AFSCs were cultured in osteogenic medium supplemented with either a CD73 
blocking peptide (OST DIF + CD73i) or with the CD73 downstream product 
adenosine (OST DIF + Adenosine) for 3 weeks. (A) The relative expression of 
Col1, OP, OC, and Rux2 to the differentiated control was detected by RT-PCR. 
GAPDH was used as an internal control. (B) Alizarin red staining was 
performed with or without CD73i and adenosine supplements. Data represent 
mean ± SEM for 3 samples per group. *** =p<0.001.  
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TGF- causes upregulation of CD73 and increased osteogenic 
differentiation potential  
TGF- signalling regulates multiple cellular phenotypes, including osteogenesis 
[204, 205]. Activation of TGF- signalling enhanced osteogenesis of AFSCs 
maintained in ESC conditions. Translocation of Smad2/3 from the cytoplasm to 
the nucleus occurs upon activation of TGF- signalling [206]. By 
immunofluorescent staining, Smad2/3 was shown to be localized primarily in 
the nucleus of AFSCs maintained in both ESC conditions, whereas it was 
localized primarily in the cytoplasm of these cells under MSC conditions (Fig. 
3.6A). To further understand the role of TGF- in CD73 expression and 
osteogenesis, AFSCs were pre-treated with TGF- or TGF- inhibitor (TGF--
i) before osteogenic induction. In TGF--supplemented MSC conditions, the 
translocation of Smad2/3 into the nucleus was observed (Fig. 3.6A). 
Correspondingly, lower levels of translocation of Smad2/3 to the nucleus were 
observed in ESC conditions in the presence of TGF--i (Fig. 3.6A). Moreover, 
expression of CD73 decreased significantly in ESC conditions supplemented 
with TGF--i, whilst expression of CD73 increased in the presence of TGF- in 
MSC conditions (Fig. 3.6B). Expression of other MSC markers, such as CD105 
and CD90, were not affected by TGF- (Fig. 3.6B). 
 
The alterations of CD73 expression by TGF-/TGF--i also affected the 
osteogenic ability of AFSCs. Pre-treatment of these cells with TGF- in MSC 
conditions increased osteogenic differentiation as demonstrated by the 
upregulation of osteogenic markers (Col1 and OC) and increased calcium 
composition compared to non-treated controls (Fig. 3.6C). On the other hand, 
AFSCs pre-treated with TGF--i in ESC conditions showed a reduction in 
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osteogenic marker expression (Col1 and OC) and calcium composition but the 
decrease of calcium composition was not marked in the MSC-ESC group (Fig. 
3.6C).  
 
Together, our results demonstrate that AFSCs’ features, such as marker 
expression and differentiation ability, can be better preserved in ESC conditions 
compared to MSC conditions. In addition, we show that the increased 
osteogenic potential observed in ESC conditions occurs via TGF--dependent 
upregulation of CD73 expression.  
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Figure 3.6 
TGF- causes upregulation of CD73 and improved osteogenesis in AFSCs 
maintained in ESC conditions.  
(A) Immunofluorescent staining for Smad2/3. Nuclei were stained with DAPI 
(blue). AFSCs were cultured in MSC or ESC-MSC with and without 
supplementation with TGF- or in ESC or MSC-ESC with and without 
supplementation with a TGF- inhibitor (TGF-i). (B) The effect of TGF- on 
CD73, CD105, and CD90 expression was measured by flow cytometry. Mean 
fluorescence intensity (MFI) was analyzed by Flowjo. (C) AFSCs cultured in 
MSC or ESC-MSC conditions supplemented with TGF- (Pre-TGF-) or a TGF-
 inhibitor (Pre-TGF--i) for 10 days underwent osteogenic induction for 3 
weeks. RNA samples were then collected for the detection of osteogenic 
markers (Col1 and OC). Cells were subsequently stained with Alizarin Red to 
highlight areas of calcium deposition. Data represent mean ± SEM. Three 
samples were examined in all the experiments. *=p<0.05. 
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AFSCs maintained in ESC conditions form EB-like structures better than 
those maintained in MSC conditions 
In addition to examining the effects of culture conditions on MSCs’ properties 
we explored the effects of culture conditions on ESCs’ properties. For example, 
the ability to form EBs in vitro which differentiate to form the three germ layers 
is a feature of pluripotent stem cells such as ESCs. Here, we performed the 
hanging drop method to test the ability of AFSCs maintained in all four 
conditions (MSC, MSC-ESC, ESC, and ESC-MSC) to form EBs. 
Morphologically, AFSCs from both ESC conditions demonstrated the ability to 
form compact, round-shaped EB-like structures similar to those formed by the 
ESC control. However, AFSCs from both MSC conditions formed more loose 
structures (Fig. 3.7A). EB-like structures were collected for total RNA extraction 
followed by RT-PCR for detection of three germ-layer markers. Expression of 
markers from each of the three germ layers (AFP, CD31, and Beta-III tubulin) 
remained the same across all conditions (Fig. 3.7B) and markedly lower than 
ESCs. Our results show that although AFSCs can form EB-like structures, the 
cells cannot differentiate into cell types from three germ layers through EB 
formation.  
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Figure 3.7 
AFSCs in all four culture conditions were able to form EB-like structures 
but not differentiate into the three germ layers. 
The hanging drop method was performed for the EB formation of AFSCs from 
different conditions. (A) Representative pictures of an EB-like structure from 
different conditions were shown. (B) EBs from different conditions were 
collected for RNA extraction and RT-PCR for detection of markers from three 
germ layers (AFP, CD31, and beta-III tubulin). Three samples were examined 
in all the experiments. 
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Endoderm and ectoderm markers increase in AFSCs in response to in 
vitro stimulation 
AFSCs demonstrated the ability to form EB-like structures but failed to 
differentiate into the three germ layers. Endoderm and ectoderm differentiation 
conditions in vitro have been well established. Here, AFSCs from all four 
conditions were subjected to in vitro differentiation protocols to examine their 
endoderm and ectoderm differentiation abilities. After induction with the 
appropriate differentiation medium, immunostaining was performed for either 
endoderm or ectoderm markers. The endoderm marker, FoxA2 (Fig. 3.8A), and 
ectoderm marker, beta III tubulin (Fig. 3.8B), were shown to increase compared 
to undifferentiated control samples in AFSCs subjected to the respective 
differentiation protocols. ESCs were used as a positive control. Our results 
indicated that AFSCs have the potential to become cell types from different 
germ layers.     
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Figure 3.8 
AFSCs maintained in all culture conditions demonstrate the potential for 
endoderm and ectoderm differentiation in vitro.  
(A) AFSCs from all four culture conditions were stimulated with defined 
endoderm differentiation medium for a week. The early stage endoderm marker, 
FoxA2, was assessed before and after differentiation as an indicator of 
successful differentiation. (B) AFSCs were induced with ectoderm 
differentiation medium for a week. The early stage ectoderm marker, beta-III 
tubulin, was assessed before and after differentiation as an indicator of 
successful differentiation. ESCs were used as a positive control. Three samples 
were examined in all the experiments. 
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Discussion 
From a developmental point of view, AFSCs are more primitive than MSCs and 
phenotypically close to ESCs. Despite this, the conditions required to maintain 
the distinctive features of AFSCs in vitro have not yet been optimized. In this 
study, we demonstrate that the cellular identity of AFSCs can be manipulated 
by altering their culture conditions. Stem cell marker expression and osteogenic 
potential are better supported in AFSCs maintained in ESC conditions in 
comparison to MSC conditions. Upregulation of CD73 in ESC conditions 
enhanced osteogenic differentiation. Additionally, we also confirm that TGF- 
promotes the expression of CD73 in AFSCs [207]. Manipulating CD73 
expression with either TGF- or TGF--i altered the osteogenic ability of the 
cells. Our findings therefore demonstrate that ESC conditions are ideal for 
sustaining the primitive features of AFSCs, especially for osteogenic 
applications.  
 
Fetal stem cells, including AFSCs, have been shown to represent a more 
primitive stage than adult stem cells. For example they have been shown to 
express higher levels of pluripotent markers, grow faster, and possess longer 
telomeres and better differentiation abilities [133, 208, 209]. Our previous 
results have shown that prenatal transplantation of fetal stem cells, including 
AFSCs maintained in MSC conditions, into a mouse model of osteogenesis 
imperfecta (OI) has the potential to restore bone parameters such as normal 
fracture susceptibility, bone strength, bone quality and levels of inflammation 
before birth [166, 176]. Here we reveal that maintenance of AFSCs in ESC 
culture conditions can enhance their osteogenic differentiation ability compared 
to current standard MSC culture conditions based on DMEM medium. Our 
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results indicate that different culture conditions can alter cellular phenotypes, 
even when introduced to AFSCs lines already established in other conditions. 
AFSCs maintained in ESC conditions may therefore provide a better source of 
therapeutic cells for treating bone diseases and other diseases. Moreover, 
understanding the mechanisms underlying the role of culture conditions on cell 
phenotype will be beneficial in allowing us to tailor these conditions to suit 
particular applications. In this study, we show that the TGF-/CD73/adenosine 
pathway is involved in enhancing the osteogenic differentiation capacity of 
AFSCs. TGF- is present in Nutristem (<5 ng/ml) but absent or at low levels in 
other basal media that are commonly used to culture the cells in MSC 
conditions. The amniotic fluid contains nutrients and growth factors that 
regulate fetal growth and development, such as TGF- [210, 211]. TGF- plays 
a key role at the later stages of gestation when cell migration is stimulated to 
accelerate the healing of intestinal wounds [211]. Therefore, the composition of 
Nutristem, which includes TGF-, may be closer to the composition of human 
amniotic fluid and may therefore contribute to the cells regaining a more 
primitive phenotype, whilst culture in MSC conditions may induce the 
differentiation of the cells and thus reduce self-renewal potential. TGF- 
signalling could therefore be targeted to improve future bone treatments using 
AFSCs.  
 
At the molecular level, TGF- upregulates the expression of CD73 through 
activating the NT5E gene via Smad2/3 [212]. This pathway has been shown to 
be activated in ESC conditions. Expression of CD73 is not only a defining 
feature of MSCs but also a key regulator of osteogenesis; inhibition of CD73 
reduces osteogenic differentiation of MSCs in vitro. Similarly, in an in vivo study, 
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CD73-deficient mice exhibited osteopenia and decreases in osteoblast marker 
expression [202]. CD73 is an ecto-5’-nucleotidase that converts AMP to 
adenosine [213]. The role of CD73 in generating adenosine has been 
suggested as a potential mechanism regulating osteogenesis, especially 
through adenosine A1 receptor (A1R) [214]. An appropriate balance between 
osteoblast activity, which contributes to new bone formation, and osteoclast 
activity, which causes bone resorption, sustains bone functionality. Locally-
released adenosine regulates the differentiation and function of both 
osteoblasts and osteoclasts. Extracellular accumulation of adenosine results in 
the activation of adenosine receptors. There are four adenosine receptors, A1R, 
A2AR A2BR, and A3R [203]. Under normal physiological levels of adenosine, A1R 
is activated to induce osteoclast differentiation [215], but when adenosine levels 
rise above normal physiological concentrations, the other receptors are 
activated, inhibiting osteoclast differentiation by decreasing IL1 and TNF 
secretion [216]. In contrast, in osteoblasts, activation of A2R increases 
osteoblast differentiation and bone formation by activating the expression of 
osteoblast-related genes [203].  
 
Along with regulating bone formation and absorption, adenosine controls 
cartilage homeostasis in bone. Mice lacking CD73 developed osteoarthritis as 
a result of destruction of cartilage and injecting adenosine into this mouse 
model has been shown to prevent the development of osteoarthritis [217]. In 
addition to its role in bone, adenosine also plays a part in regulation of 
inflammation. Extracellular adenosine can regulate the inflammatory response 
by suppressing pro-inflammatory cytokines and stimulating anti-inflammatory 
cytokines [218]. When infection occurs, ATP accumulates, which then triggers 
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proinflammatory cytokine production. However, degradation of ATP to AMP by 
CD39 followed by dephosphorylation of AMP to adenosine decreases the 
inflammatory signal. For example, generation of adenosine from regulatory T 
cells can inhibit the activity of effector T cells and, through paracrine effects, 
increase the immunosuppressive activity of neighbor regulatory T cells [219]. 
Our findings indicate that the presence of TGF- in Nutristem promotes the 
osteogenic differentiation of AFSCs in vitro, providing a strategy to augment the 
osteogenic potential of the cells for the treatment of bone pathologies.   
 
Our results confirm that TGF- regulates CD73 expression, which, in turn, 
enhances osteogenic differentiation. TGF- signalling has been reported to be 
a key regulator of osteogenic differentiation but various additional signalling 
pathways are involved in controlling osteogenesis, including Wnt signalling 
[220]. Wnt is a complex signalling molecule controlling multiple cellular 
phenotypes, including the proliferation and differentiation of different types of 
stem cells. Activation of Wnt signalling has been shown to induce osteogenesis 
by upregulating osteogenic markers, such as Runx2 and Dlx5 [220], and 
suppressing factors that lead to differentiation into other cell types, such as 
PPARγ for adipogenesis [221]. On the other hand, inhibition of Wnt signalling 
has been shown to lead to decreases in bone density [222, 223]. Furthermore, 
adenosine-regulated osteogenic differentiation has also been linked to the Wnt 
pathway. Expression of CD73 increased with activation of Wnt signalling via the 
TCF-1 transcription factor and decreased in response to inhibition of Wnt 
signalling [224]. Activation of TGF- signalling in ESC conditions contributes to 
increased CD73 expression, which results in an enhancement of osteogenesis 
in AFSCs. However, TGF- is not the only contributory factor. Further 
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investigation is required to understand, in more detail, the detailed mechanisms 
involved in regulating osteogenesis in ESC conditions. 
 
Here we demonstrate that cellular identity can be manipulated by the culture 
environment, which significantly affects both a cell’s “stemness” and its 
differentiation potential. We show that ESC culture conditions can better 
preserve the primitive stem cell phenotypes of AFSCs, including their faster 
growth kinetics and improved osteogenic differentiation ability in comparison to 
MSC culture conditions. The increased proliferation rate of AFSCs cultured in 
ESC conditions is advantageous in that it is likely to allow the generation of the 
huge number of cells required for clinical applications. Additionally, in 
comparison to MSC culture conditions which generally contain FBS, the xeno-
free ESC culture conditions used in this study further enhance the applicability 
of AFSCs in future therapies.  
 
Conclusion 
AFSCs provide a potential source of cells for prenatal and neonatal applications. 
Their broader differentiation ability, compared to MSCs, offers more potential 
for practical applications in both basic and clinical research. In addition, unlike 
ESCs, obtaining AFSCs raises no ethical issues. Despite this, the ideal culture 
conditions for preserving the optimal AFSCs properties are still not well 
documented. Here we show that maintaining AFSCs in ESC conditions can 
better preserve expression of stem cells markers and differentiation ability of 
AFSCs, especially their osteogenic potential. TGF-–mediated CD73 
expression is shown here to enhance the osteogenic potential of AFSCs 
cultured in ESC conditions, although TGF- is unlikely to be the only factor 
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involved. This study provides, for the first time, mechanistic understanding of 
how the cell culture environment affects the phenotype of AFSCs. Moreover, 
we describe the optimal AFSC culture conditions to enhance the osteogenic 
potential of AFSCs which could be used in future clinical applications of these 
cells to treat bone disease.  
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Chapter 4 
 
Cardiomyocyte differentiation potential 
of AFSCs  
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Introduction 
Cardiovascular disease is one of the leading causes of death [225, 226] and 
one of the major factors leading to the rejection of drugs from the development 
process is their adverse effects on the heart [31]. Preclinical studies are 
challenging due to the lack of availability of human cardiac cell lines. Although 
animal models can be used in preclinical tests, species variation can mean that 
the results are not directly translatable to humans [31]. The discovery of 
pluripotent stem cells offers a potential solution to these challenges, by allowing 
the generation of human cardiac cells in vitro. Pluripotent stem cells have been 
shown to have various promising applications, including cell therapy, tissue 
engineering, and drug development. Since pluripotent stem cells have the 
capacity to differentiate into functional cardiomyocytes [32, 96], they provide an 
ideal platform to study cardiovascular disease and for preclinical drug tests. 
iPSC-derived cardiomyocytes (iPSC-CM) have been shown to share 
characteristics with embryonic stem cells ESC-derived cardiomyocytes (ESC-
CM) and adult cardiomyocytes, including their morphology, gene expression 
and sarcomere organization [96, 227-229], bringing forward the potential for 
personalized medicine. However, exogenous factors are still necessary to 
generate iPSCs efficiently, raising concerns regarding integration of these 
factors into the DNA of the therapeutic cells and therefore potential 
tumorigenesis.  
 
AFSCs express markers from both ESCs and mesenchymal stem cells (MSCs) 
and are thus considered to represent an intermediate phenotype between these 
two stem cell types [103]. AFSCs have a more primitive phenotype than MSCs, 
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meaning that in addition to their mesenchymal tri-lineage differentiation 
potential they can give rise to cell types from the other two germ layers, 
ectoderm and endoderm [103]. However, since AFSCs are not pluripotent, 
there are no concerns about tumorigenesis resulting from their use in vivo. 
AFSCs may, therefore, provide a safer option than pluripotent stem cell-derived 
cells for potential cell therapies. Furthermore, AFSCs are capable of 
differentiating into cell types expressing cardiac markers when co-cultured with 
neonatal rat ventricular myocytes (NRVM) [157] or via induction with 5-Aza-2’-
deoxycytidine (5-aza) [153]. Nevertheless, these methods are only suitable for 
inducing MSCs, not pluripotent stem cells, toward cardiomyocyte-like lineages 
and none of these methods can generate spontaneous contracting 
cardiomyocytes. Although AFSCs are more primitive than MSCs and 
phenotypically close to ESCs, protocols for inducing pluripotent stem cells into 
cardiomyocytes have not been optimized for AFSCs yet.  
 
AFSCs have the potential for use in tissue engineering and cellular therapy for 
heart regeneration [17, 165]. For tissue engineering, synthetic or non-synthetic 
materials are required for heart repair, but these materials are not ideal for 
infants since they pose a challenge as the child develops. Cellular therapy 
avoids this challenge and presents the opportunity to treat infants with 
autologous AFSCs. AFSCs have not yet been approved for clinical use, 
however, animal studies have demonstrated promising therapeutic benefits in 
cardiovascular disease models. By transplanting AFSCs in the heart of animals 
with ischemia/reperfusion injury, AFSCs have been found to engraft and 
express endothelial (vWf) and cardiac (cTnT) markers. In addition, the ejection 
fraction, measured by MRI, was improved [158]. Another study by Lee et al. 
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demonstrated similar findings. AFSCs injected intramyocardially attenuated the 
progression of heart failure and increased wall motion in acute myocardial 
infarction models. In addition to differentiating into cardiomyogenic lineages, 
AFSCs also contributed to increasing vessel densities at the infarct site by 
upregulating growth factors such as HGF, bFGF and VEGF [164]. Although 
previous studies have demonstrated the potential clinical benefits of AFSCs to 
treat cardiovascular disease, generating mature and functional cardiomyocytes 
from AFSCs in vitro is still beneficial. Not only will the process provide further 
understanding of the mechanisms by which AFSCs contribute to the treatment 
of cardiovascular disease in vivo, it may mean that AFSCs can be used in a 
similar way to iPSCs in drug development and disease modeling. 
 
Aims 
We have shown in the previous chapter that AFSCs maintained in ESC 
conditions preserved better stem cells markers and exhibited a greater ability 
to differentiate. AFSCs, maintained in both MSC and ESC conditions, will here 
be tested with the Wnt-dependent differentiation protocol established on 
pluripotent stem cells. Cardiac markers, calcium transient, and beating 
cardiomyocytes will be investigated and compared between different conditions.  
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Materials and Methods 
AFSCs culture 
AFSCs were obtained as described in Chapter 3. AFSCs maintained in both 
MSC and ESC conditions were used in this study. In brief, cryopreserved 
samples were thawed in a water bath and transferred to 5 ml of culture medium 
(Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen)) supplemented with 
10% fetal bovine serum (FBS) (Biosera), 2 mM L-Glutamine, 50 IU/ml penicillin 
and 50 mg/ml streptomycin (Gibco-BRL) or Nutristem. Cell pellets were 
collected by centrifugation and resuspended in the culture medium before 
plating into a 10-cm tissue culture dish. 
 
iPSCs culture 
Human induced pluripotent stem cell line, IMR-90, was used in this study. Cells 
were maintained in a Matrigel-coated well in a 6-well plate with Essential 8 
medium. The medium was replaced every day. To split the cells, the medium 
was removed, followed by the addition of 2 ml of 0.5 mM EDTA and it was then 
incubated for 7 min. The EDTA was then removed and the well was left blank 
for 1 min at room temperature. 2 ml of Essential 8 medium was then added to 
the well and cells were collected in clusters with a 1 ml wide tip. The cells were 
then plated into the new well (1:6 ratio) in 2 ml Essential 8 with 1 mM of Rock 
inhibitor.   
 
Cardiomyocytes differentiation from iPSCs 
IMR-90 were seeded in a 6-well plate as described above. When the cells 
reached 90% confluency, the medium was replaced by RPMI plus B27 minus 
insulin (RPMI-INS) with 6 µM of CHIR99021, a GSK3β inhibitor leading to 
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activation of canonical Wnt pathway, for two days’ incubation, after which, the 
medium was switched to RPMI-INS only for another day’s incubation. Twenty 
four hours later, cells were then treated with RPMI-INS with 2.5 µM C59, a 
porcupine (PORCN) inhibitor blocking secretion of Wnt protein, for another two 
days. Following this, the medium was replaced every other day with RPMI-INS. 
Contracting cardiomyocytes could be seen around day 8 to day 12, whereupon 
the medium was switched to RPMI plus B27 with insulin (RPMI+INS) and 
changed every other day. Cardiomyocytes were incubated until maturation at 
day 30.  
   
Cardiomyocytes differentiation from AFSCs 
AFSCs from both conditions were seeded on a Matrigel-coated tissue culture 
plate with their original medium. When the cells reached 90% confluency, the 
medium was changed to a differentiation medium, as shown in Table 4.1. In 
addition to the Wnt-dependent protocol, 5-aza was incubated with the cells for 
one day and conditioned medium was collected from iPSC-CM. Samples were 
collected at day 15 for further analysis.  
 
Optimization of the experimental concentration of Wnt compounds 
Fifty thousand AFSCs from both MSC and ESC conditions were seeded in the 
wells of a 6-well plate with their own media. Twenty four hours after plating, the 
media were switched to RPMI-INS with varying concentrations of CHIR99021 
(2 µM, 3 µM, 4 µM, and 6 µM) for two days’ incubation. 3 µM of CHIR99021 
was selected as an experimental concentration. For the C59 test, AFSCs were 
first seeded in wells in a 6-well plate followed by two days’ incubation with 3 µM 
of CHIR99021. Afterwards, the medium was switched to RPMI-INS with a 
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different concentration of C59 (2.5 µM, 5 µM, 10 µM, and 20 µM) for another 
two days’ incubation. 5 µM of C59 was selected as an experimental 
concentration. 
 
Immunofluorescence staining 
For immunostaining, 10,000 cells were seeded on coverslips. Twenty four hours 
later, 4% paraformaldehyde was introduced for fixation in a 10 min incubation 
followed by permeabilization with 0.5% Triton-X100 in PBS for 15 min. Samples 
were then washed with PBS and incubated with blocking buffer, PBS + 5% 
normal goat serum, one hour at room temperature. Samples with primary 
antibody (cTroponin T, 1:200, AB45932, Abcam and Alpha-actinin, 1:200,  
AF7811, Sigma-Aldrich) were incubated with the blocking buffer overnight at 
4C. Samples were then washed with PBS and incubated with a secondary 
antibody (A11008, ThermoFisher) for one hour at room temperature. After the 
samples had been washed with PBS, DAPI was then used for nucleus staining. 
Images were collected with a confocal microscope (Zeiss LSM7100).  
 
RNA extraction and cDNA synthesis 
The cell pellet was collected with TrypLE followed by centrifugation. The total 
RNA was extracted using RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. 1µg of RNA was then used as templates for cDNA 
synthesis using High Capacity cDNA Reverse Transcription Kits (Thermo 
Scientific) (according to the manufacturer’s instructions). 
 
Real-Time PCR 
The generated cDNA was amplified using the ABI StepOne Sequence Detector 
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system (Applied Biosystems) with the Taqman Assay system, MESP 
(Hs00251489), GATA4 (Hs00171403), TNNT2 (Hs00165960), and MYH6 
(Hs01101425). Samples were normalized against the internal control, GAPDH 
(Hs02758991). 10 ng of cDNA was used in each well.  
 
Electrophysiology 
After the simulation of the Wnt-dependent differentiation protocol, AFSCs were 
collected and re-plated in MatTek dishes. Ca2+ dynamics were studied using 
Fluo-4AM loaded cells imaged with a Nikon Eclipse T6200 and a Redshirt 
NeuroCMOS camera at 0.5KHz with 1Hz, 20V, 15ms field stimulation. 
 
Statistical analysis 
Different differentiation conditions were compared to parental controls 
(undifferentiated) and between each condition. Comparisons between groups 
were made by using ANOVA. The p values ≤0.05 were considered significant. 
The results were calculated using GraphPad-7 (GraphPad, San Diego, CA, 
USA). Data were expressed as meanSEM (standard error of the mean). 
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Results 
Optimization of the experimental concentrations of Wnt compounds, 
CHIR and C59 
AFSCs maintained in both conditions were seeded in six-well plates in their 
original media. Twenty four hours later, the media was replaced with RPMI-INS 
supplemented with the appropriate concentration of CHIR (2 µM, 3 µM, 4 µM, 
and 6 µM) for 2 days. Cells in both conditions exhibited severe cell death (bright 
dot, non-adherent cells) in response to 4 µM and 6 µM CHIR treatment whilst 
AFSCs exposed to 2 µM and 3 µM CHIR treatment remained alive (adherent 
cells) and continued proliferating (Fig. 4.1A). 3 µM CHIR was therefore selected 
as the concentration for differentiation protocol since this was the highest 
concentration that had no deleterious effects. To optimize the working 
concentration of C59, AFSCs were treated with 3 µM CHIR for 2 days before 
the medium was changed to RPMI-INS supplemented with the appropriate 
concentration of C59 (2.5 µM, 5 µM, 10 µM, and 20 µM) for an additional 2 days. 
Severe cell death (bright dot, non-adherent cells) was not observed in ESC 
condition with any concentration of C59 (Fig. 4.1B). However, in response to 10 
µM or 20 µM of C59, cell death was observed in the MSC condition but not with 
2 µM and 5 µM (Fig. 4.1B). Therefore, 5 µM of C59 was selected for the 
differentiation protocol.   
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Figure 4.1 
A 
 
B 
 
 
Figure 4.1 
Optimization of the concentration of CHIR and C59 
AFSCs from both MSC and ESC conditions were tested with different 
concentration of CHIR and C59 (as shown above). (A) Cells were treated with 
different concentration of CHIR for 2 days. Representative pictures were shown. 
(B) AFSCs were treated with 3 µM of CHIR 2 days prior to the treatment of C59. 
Cells were then treated with different concentrations of C59 for 2 more days 
and representative pictures were shown.  
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Optimal differentiation conditions were dependent on the original culture 
medium 
AFSCs were differentiated using the Wnt-dependent protocol for pluripotent 
stem cells (Fig. 4.2). In addition to the Wnt protocol, AFSCs from both 
conditions were also exposed to various combinations of 5-aza and conditioned 
medium collected from iPSC-CM as shown in Table 4.1. After 15 days of 
induction, cells were re-plated for immunostaining and RNA samples were 
collected for further analysis. During cardiac differentiation, cells undergo a 
transition from early cardiac progenitors to mature cardiomyocytes. Thus 
expression of MESP, an early cardiac mesoderm marker, GATA4, a cardiac 
progenitor marker, TNNT2 and MYH6, both mature cardiomyocyte markers, 
were examined by real-time PCR. MESP was downregulated across all 
induction conditions in both MSC and ESC media (Fig. 4.3A). In MSC 
conditions, MESP decreased significantly with stimulation of different 
combinations of chemicals, except CM+5-aza. Among all the conditions with 
conditioned medium, CM2+Wnt, CM+5-aza+Wnt and CM2+5-aza+Wnt 
showed a significant decrease compared to conditioned medium only (Fig. 
4.3A). These results indicate that manipulating Wnt signalling induces further 
differentiation than conditioned medium alone.  
 
Similar results were observed with iPSC-CM exposed to the Wnt protocol, early 
stage cardiac markers decreased in cells as they reached a fully-differentiated 
stage [96]. GATA4 was not detected in any of the AFSC samples but was shown 
to increase in iPSC-CM. TNNT2 increased in AFSCs exposed to all induction 
conditions (Fig. 4.3A), especially in MSC conditions with conditioned medium 
and Wnt (Fig. 4.3A). However, another mature cardiac marker, MYH6, was not 
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detected in any of the samples, which may relate to the observation of a lack of 
contracting cells in any condition. Moreover, expression of Troponin and α-
actinin were also confirmed by immunostaining. Conditioned medium in 
combination with the Wnt protocol caused the greatest increase in expression 
of Troponin and α-actinin (Fig. 4.3B, Fig. 4.3C). Different chemicals with 
conditioned medium showed a stronger signal than with RPMI-INS medium (Fig. 
4.3B, Fig. 4.3C). The addition of conditioned medium in combination with the 
Wnt protocol caused greater increases in the expression of Troponin compared 
to conditioned medium alone (Fig. 4.3B, Fig. 4.3C). Additionally, in MSC 
conditions, CM+Wnt caused a higher expression of Troponin than CM+5-aza, 
RPMI+Wnt and RPMI+5-aza (Fig. 4.3C). These results demonstrate that 
manipulating Wnt signalling in the presence of conditioned medium is the 
optimal condition for AFSCs differentiation along the cardiac lineage. Another 
mature marker, -actinin, showed similar results as Troponin. Expression of -
actinin was less induced in conditioned medium only compared to the other 
groups containing conditioned medium with chemicals (Fig. 4.3B, Fig. 4.3C). 
Furthermore, the combination of chemicals and conditioned medium induced 
more -actinin expression than chemicals with RPMI-INS medium alone (Fig. 
4.3B, Fig. 4.3C). In addition, the Wnt protocol gave higher expression levels of 
-actinin than the condition without the Wnt protocol (Fig. 4.3B, Fig. 4.3C). 
However, both Troponin and -actinin expression in AFSCs did not show 
mature sarcomere structure as seen in fully-differentiated cardiomyocytes, like 
iPSC-CM, and spontaneous contracting cells were not observed from any 
condition. Despite this, our results indicate that AFSCs can differentiate better 
to the cardiac lineage when exposed to the Wnt protocol. 
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Figure 4.2 
 
 
Figure 4.2 
Graphic protocol of the Wnt-dependent differentiation 
Fresh AFSCs pellet was collected by centrifugation. The cell pellet was then 
split into two, one part in the MSC condition (DMEM + 10% FBS) and another 
part in the ESC condition (Nutristem + Matrigel). Cells were then seeded onto 
a 6-well plate followed by the Wnt-dependent cardiomyocytes differentiation 
protocol. After 15 days’ induction, cells were characterized by real-time PCR, 
immunostaining, and electrophysiology tests. 
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Table 4.1 
 
 
Table. 4.1 
Different conditions for cardiomyocytes differentiation.  
AFSCs from both the MSC and the ESC conditions were induced with various 
combinations of conditioned medium collected from human iPSC-CM, 5-aza, 
Wnt compounds, and RPMI-INS medium. Samples were collected after 15 days 
for further analysis.  
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Figure 4.3 
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Figure 4.3 
Differentiation conditions induced expression of cardiac markers in 
AFSCs from both culture media.  
(A) Real-time PCR was performed to analyze the expression of cardiac markers 
from different stages (MESP and TNNT2) compared to parental controls. 
GAPDH was used as an internal control. (B) Immunostaining with Troponin and 
-Actinin was performed with samples from all induction conditions. (C) The 
intensity of cell fluorescence was measured by ImageJ software. AFSCs in 
MSC and ESC culture conditions were parental controls and human iPSC-
derived cardiomyocytes (iPSC-CM) were positive controls. The scale bar is 50 
µm. Experiments were done in triplicate. N.D.=Non-detected. * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001 and **** p ≤ 0.0001 
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Expression of cardiac markers was induced in AFSCs from both ESC and 
MSC conditions in a trans-well co-culture system with iPSC-CM. 
Expression of cardiac markers was induced with direct stimulation of the AFSCs 
under various differentiation conditions from MSC and ESC media. It has been 
reported that the expression of cardiac markers can be induced by co-culturing 
AFSCs with neonatal rat ventricular myocytes (NRVM). Here, we co-cultured 
AFSCs from both conditions with human iPSCs-derived cardiomyocytes (iPSC-
CM) and stimulated them with the Wnt protocol supplemented with 5-aza and 
conditioned medium. Samples were collected after 15 days’ induction for further 
analysis. Real-time PCR analysis showed that MESP, like direct stimulation, 
decreased significantly across all conditions (Fig. 4.4A). The cardiac progenitor 
marker, GATA4, was still undetectable with the co-culture system. TNNT2 was 
induced in all groups and AFSCs from the MSC condition showed a greater 
increase than the ESC condition, which is similar to direct stimulation (Fig. 4.4A). 
However, MYH6 was still undetected in any group and spontaneous contracting 
cells were still absent. Additionally, the expression of Troponin and α-actinin 
were confirmed by immunostaining (Fig. 4.4B). Conditioned medium in 
combination with chemicals demonstrated higher expression of Troponin 
compared to conditions with RPMI-INS medium (Fig. 4.4C). Similar results were 
observed with -actinin (Fig. 4.4B, Fig. 4.4C). However, as direct stimulation, 
mature sarcomere structure was not seen in any induction conditions in AFSCs 
from both MSC and ESC media.  
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Figure 4.4 
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Figure 4.4 
AFSCs induced with the Wnt protocol in a co-culture system with iPSC-
CM expressed cardiac markers.  
(A)  The expression of cardiac markers from different stages (MESP and 
TNNT2) compared to the parental controls was examined by real-time PCR. 
GAPDH was used as an internal control. (B) Immunostaining was performed to 
show the expression of Troponini and -Actinin with samples from all induction 
conditions. (C) The intensity of cell fluorescence was measured by ImageJ 
software. AFSCs in MSC and ESC culture conditions were the parental controls 
and human iPSC-derived cardiomyocytes (iPSC-CM) were the positive control. 
Scale bar was 50 µm. Experiments were performed in triplicate. N.D.=Non-
detected. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001 
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Wnt-induced AFSCs with cardiac markers showed no response to electro 
stimulation.  
To obtain further confirmation of the maturation status of, an electrophysiology 
test was performed. AFSCs were induced with the Wnt protocol. After 15 days, 
Ca2+-dynamics was investigated. Spontaneous contraction was not detected 
across all the test groups (Fig. 4.5). Moreover, with 1 Hz stimulation, contraction 
was still not observed in AFSCs with cardiac markers expression (Fig. 4.5). Our 
results showed that AFSCs induced with the Wnt protocol demonstrated limited 
cardiomyocyte differentiation.  
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Figure 4.5 
 
 
Figure 4.5 
Electrophysiological characterization of Wnt-induced AFSCs with 
expression of cardiac markers.  
In order to test the contractile ability of Wnt-induced AFSCs, samples were 
tested with Ca2+ dynamics with (blue) and without (black) electrical stimulation 
(1 Hz). iPSC-CM were used as a positive control (IMR-90-CM).   
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Discussion 
AFSCs have been shown to be a promising cell source with various advantages 
over adult MSCs. For example, AFSCs are more primitive than adult MSCs, 
meaning that they can differentiate into multiple cell types from each of the three 
germ layers [103]. However, AFSCs are not pluripotent, which removes the risk 
of tumorigenesis associated with pluripotent cells, and there are no ethical 
issues associated with their use. These features make AFSCs an ideal 
candidate for tissue engineering and cell therapy, particularly for autologous 
use in infants to treat congenital defects. 
 
Several studies have demonstrated the therapeutic benefits of AFSCs by 
injecting them into animal models of myocardial infarction [164] and also their 
potential to differentiate along the cardiac lineages. Various differentiation 
methods have been demonstrated. For example, co-culture with 
cardiomyocytes [157] and induction with 5-aza [153] are the most common 
approaches. However, whilst these protocols induce the expression of cardiac 
markers, contracting cells are not observed. These results indicate that AFSCs 
require additional cues to become mature cardiomyocytes. Since AFSCs 
represent an intermediate stage between ESCs and MSCs, we tested the Wnt-
dependent differentiation protocol, established on pluripotent stem cells, on 
AFSCs both alone and in combination with a co-culture system and 5-aza 
stimulation. However, limited differentiation was observed in AFSCs exposed 
to the Wnt-dependent protocol. Unlike both ESCs and iPSCs, AFSCs only 
increased the expression of some cardiac markers and contracting cells were 
not observed in any of the protocols tested. Additionally, although AFSCs 
expressed cardiac markers after induction, a mature sarcomere structure was 
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not observed, indicating that AFSC-derived cardiomyocytes may only represent 
an early stage of cardiomyocyte differentiation. Similar results were found with 
5-aza and the co-culture system, whereby upregulation of cardiac markers was 
observed but spontaneous beating cells were absent. AFSCs induced by the 
Wnt-dependent protocol showed comparable results to previous studies.       
 
In the previous chapter, we demonstrated that primitive AFSCs’ features such 
as stem cell markers and differentiation ability can be maintained better in ESC 
conditions than MSC conditions. Additionally, higher expression of CD73 was 
observed in AFSCs maintained in ESC conditions, leading to better 
osteogenesis. In addition to its role in osteogenesis, CD73 has been shown to 
be involved in cardiomyocyte differentiation of MSCs. Adipose-derived MSCs, 
which were highly CD73 positive demonstrated better potential to differentiate 
into cardiac lineages compared to the CD73 negative population in vitro [230]. 
Due to their increased stemness, AFSCs maintained in ESC conditions were 
expected to produce fully-differentiated cardiomyocytes when exposed to the 
Wnt-dependent protocol with higher efficiency than those maintained in MSC 
conditions. However, our results showed that AFSCs maintained in MSC 
condition exhibited higher levels of expression of cardiac markers compared to 
those maintained in ESC condition. Since cardiomyocytes are part of the 
mesodermal lineage, MSC condition may cause the cells to become more 
mesenchymal-like. Alternatively, ESCs are epithelial-like so AFSCs maintained 
in ESC condition are likely to enter a more primitive, undifferentiated state. This 
difference may explain why AFSCs maintained in MSC condition give rise to 
mesodermal cell types such as cardiomyocytes with higher efficiency.  
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Overexpression of cardiac markers has been shown to induce MSCs to 
differentiate along the cardiac lineage. For example, myocardin, a transcription 
coactivator of cardiac muscle involved in regulating the expression of various 
cardiac markers, such as Troponin T, MHC, and GATA4, has been shown to 
have this effect. Overexpressing myocardin in iPSC-derived MSCs has been 
shown to increase the expression of MHC, GATA4 and -actinin and the 
conduction velocity of MSCs increased significantly as well. However, 
spontaneous contraction was not reported [231]. In order to further our 
understating of the additional factors required to differentiate AFSC-derived 
cardiomyocytes towards more mature or even functional cardiomyocytes, 
overexpression of cardiomyocytes marker genes, which are absent in these 
cells, should be performed. For example, MHC plays a vital role in the 
contractile activity of cardiomyocytes, but its expression was not observed in 
any of the differentiation protocols tested. Overexpressing MHC in AFSC-
derived cardiomyocytes is likely to not only provide information about the further 
factors necessary to cause cardiomyocyte maturation but also the role of the 
protein in AFSC-derived cardiomyocytes.  
 
In addition to cardiac markers, overexpressing other molecules, such as micro-
RNA (miRNA), has been reported to improve cardiac differentiation of MSCs. 
Several miRNAs that induce stem cells to adopt a cardiac fate have been 
identified. For example, overexpressing miRNA1-2 in MSCs followed by 
treatment with 5-aza, resulted in increased expression of cardiac markers such 
as Nkx2.5, Troponin T and GATA4 in comparison to the 5-aza only condition. 
Lower levels of apoptosis were observed as well [232]. Nevertheless, not all 
miRNAs positively regulate cardiac differentiation. For example, miRNA-124 
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was found to be downregulated during cardiac differentiation. Inhibiting miRNA-
124 enhanced expression of ANP, Troponin and MHC in induced MSCs. 
Potassium channel currents were increased in response to miRNA-124 
inhibition [233]. The role of a number of additional molecules in cardiac 
differentiation has been established. Induction of these molecules in Wnt-
induced AFSCs might provide further information on how to reach the mature 
cardiomyocyte stage.   
 
As mentioned, manipulating the expression of various molecules can enhance 
the cardiac differentiation potential of MSCs, likely due to their effects on 
signalling pathway activity [232, 233]. These findings suggest that directly 
modifying the signalling pathways involved in cardiac differentiation may 
promote the maturation of Wnt-induced AFSCs. The protocols tested led to the 
expression of Troponin and α-actinin but not the development of a mature 
sarcomere structure. Sarcomere structure formation is pivotal for contractility. 
Other studies have demonstrated the complex cell signalling activity that is 
involved in regulating the organization of the sarcomere structure. Therefore 
stimulating Wnt-induced AFSCs with agonists or antagonists of these signalling 
pathways may promote the maturation of the sarcomere structure. For instance, 
serum response factor (SRF) is essential for maintaining sarcomeric integrity in 
cardiomyocytes and troponin has also been shown to be a downstream target 
of SRF [234]. Overexpression of AFSCs with SRF may, therefore, enhance the 
formation of a mature sarcomere structure, potentially contributing to 
spontaneous contraction. 
 
In addition to their in vitro differentiation capacity, AFSCs and other MSCs have 
170 
 
been shown to have therapeutic benefits against cardiac diseases in vivo. 
However, even in in vivo conditions, limited cardiomyocyte differentiation has 
been demonstrated; cardiac marker expression is observed but there is no 
evidence of spontaneous contraction. Due to the lack of convincing evidence 
of functional cardiomyocyte differentiation upon transplantation, AFSCs and 
MSCs are considered to contribute to cardiac regeneration by manipulating the 
niche surrounding damaged tissues. In response to injection of MSCs into acute 
myocardial infarction mouse models, macrophages were recruited to the 
injured site to facilitate cardiac repair by promoting angiogenesis. In addition to 
recruiting other cell types, MSCs were able to attenuate fibrosis by secreting 
bone morphogenetic protein (BMP), which reversed the fibrogenic effect of the 
macrophages [235]. Moreover, in vivo endothelial differentiation was reported 
to occur with MSCs treatment, likely in response to vascular endothelial growth 
factor (VEGF) secretion by MSCs. In addition to angiogenesis, MSCs have anti-
inflammatory and immunomodulatory effects [236]. Following ischemia, 
irreversible cell death results in necrosis of various cell types in the heart, thus 
leading to severe inflammation. The inflammatory response then affects the 
size of the scar that is formed. Intramyocardial injection of MSCs in myocardial 
infarction models led to decreases in the levels of proinflammatory cytokines 
and therefore the formation of a smaller scar [237]. Moreover, MSCs treatment 
reduced neutrophil infiltration in the infarcted heart by inducing apoptosis. 
Decreasing the numbers of neutrophils also diminished the levels of adverse 
factors they secrete, such as reactive oxygen species, and prevented their 
recruitment [238, 239].  
 
MSCs have the potential to treat a variety of cardiac diseases. However, it 
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remains unclear whether AFSCs or MSCs can contribute to cardiac 
regeneration by directly differentiating into functional cardiomyocytes. To further 
our understanding of the therapeutic mechanisms of AFSCs or MSCs, the 
differentiation conditions required to obtain fully differentiated cardiomyocytes 
from these cells are still needed. 
 
Conclusion 
AFSCs have been demonstrated to possess the potential to differentiate 
towards a cardiomyocytes lineage. However, only cardiac markers have been 
shown with the induction of current protocols and contracting cells have not yet 
been observed. Here, we tested the Wnt-dependent protocol, established for 
differentiating pluripotent stem cells into mature cardiomyocytes, with AFSCs. 
Our results demonstrate limited differentiation with an increase only of some 
cardiac markers, as shown in other studies. Although AFSCs are considered to 
share features with pluripotent stem cells, the Wnt-dependent protocol is not 
suitable for fully differentiating AFSCs into mature cardiomyocytes. To fully 
ascertain the potential of AFSCs to differentiate into cardiomyocytes, further 
studies need to be done.   
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Chapter 5 
 
Conclusions / Future directions 
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Mechanisms involved in VPA-induced AFSC reprogramming 
AFSCs are more primitive than adult MSCs and phenotypically closer to ESCs, 
however, AFSCs are not pluripotent. Various approaches, such as with 
Yamanaka factors or nuclear transfer, have been established which show that 
somatic/stem cells can be reprogrammed to regain functional pluripotency [23, 
35]. Reprogrammed cells not only express pluripotent markers but are also 
capable of differentiating into the three germ layers in vitro and in vivo and 
contribute to chimeric offspring. Although tumorigenesis, from mutations or 
pluripotency, remains a concern, iPSCs still represent a new era in applications 
of pluripotent stem cells, such as personalized medicine. Nevertheless, 
integration of the genome and efficiency remain issues with generating iPSCs. 
Our lab and others have demonstrated that cells can be reprogrammed 
chemically without introducing any extrinsic factors, like Yamanaka factors [59, 
60]. Chemically reprogrammed cells also showed functional pluripotency as 
iPSCs but without the concern of genomic integration. In addition, the VPA-
induced AFSC reprogramming protocol, established in our lab, is simple and 
efficient, and involves maintaining AFSCs in ESC conditions with VPA 
stimulation. However, the high sensitivity of AFSCs to the culture environment 
resulting in low reproducibility is still a challenge. Several methods to restore or 
optimize the original protocol have been examined, such as using different 
concentrations of VPA, shortening the duration of the initial stage, and applying 
different ESC conditions, but, at present, the protocol remains unrestored.  
 
Measurement of the effect of VPA on AFSCs 
Although various concentrations of VPA have been examined in this study, it is 
yet to be determined whether the effect of VPA on AFSCs is functional or not. It 
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must be considered that the failure of VPA-induced reprogramming might be 
due to ineffective VPA. VPA is a known histone deacetylase inhibitor so by 
measuring histone deacetylation can provide information. Moreover, it has been 
reported that VPA may enhance the expression of Oct-4, a pivotal factor for 
sustaining pluripotency and reprogramming. Isaji and colleagues showed that 
the presence of VPA in the 4-cell stage of nuclear transferred blastocysts 
improved the expression of Oct-4 [240]. In addition, Teng et al. demonstrated 
that VPA can directly activate the Oct-4 promoter through a PI3K/Akt/mTOR 
signalling pathway [196]. It would be prudent to examine this signalling pathway 
or alternatively the activity of Oct-4 promoter in the treated AFSCs. Even though 
this effect has not yet been validated in AFSCs, treating the cell lines used in 
other studies could provide a positive control for the effect of VPA. This might 
then be used to eliminate one possible reason for unsuccessful reprogramming 
from VPA.  
 
Evaluation of different media for reprogramming 
Different types of media from various suppliers are commonly used to maintain 
cell pluripotency in vitro. Primate ESC medium, a fibroblast feeder-dependent 
culture condition, was the first medium used to reprogram human fibroblasts by 
Yamanaka and his team. In order to avoid the potential variability from the 
fibroblast feeder, a feeder-free medium was introduced, for example, Nutristem, 
mTesr or Essential 8 media [77]. Nutristem is the medium used for VPA-induced 
reprogramming. However, as addressed in the previous chapter, lot-to-lot 
variation is an issue resulting in unsuccessful reprogramming. Although other 
feeder-free media, like mTesr and Essential 8, have been examined by other 
lab members to re-establish the protocol, successful reprogrammed AFSCs 
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have still not been observed. Due to business confidentiality, it is difficult to 
obtain any information on the components of commercial media.  
 
Hou and colleagues have demonstrated a chemically-defined condition to 
acquire pluripotent stem cells from mouse fibroblasts and adult stem cells 
(CiPSCs) without Yamanaka factors [59]. CiPSCs are reprogrammed and 
sustained in the defined media. Since this protocol and our VPA-induced 
protocol are both extrinsic factor-free, further investigation into using their 
defined media in the VPA-induced protocol is warranted. Additionally, this 
chemically-defined condition has been evaluated on adult stem cells, lessening 
the concern of chemically-induced differentiation. However, to date this protocol 
has only been demonstrated on adult mouse samples which differ from human 
AFSCs not only in the species involved but also their maturity level. Further 
optimization of the application of chemically-defined media into the VPA 
protocol is still required. 
 
Optimization of VPA protocol with other chemicals  
In addition to the defined media, there is value in testing other chemicals used 
in obtaining CiPSCs in the VPA protocol. The screen could involve a similar 
strategy as used by Yamanaka for the definition of the four factors required for 
induced pluripotency. Seven small molecules, including VPA, were selected by 
Hou et al. Each of the seven chemicals can be used to replace the VPA in the 
VPA protocol to observe whether any successfully reprogrammed cells are 
obtained. In addition to testing each chemical individually, the seven chemicals 
can be introduced together. If AFSCs can be reprogrammed successfully with 
the application of the seven chemicals, withdrawing one chemical from the pool 
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can determine the critical chemicals for reprogramming AFSCs. In this way, 
optimized conditions could be acquired for a reproducible protocol to reprogram 
AFSCs.   
 
Due to the fact that the original VPA-induced reprogramming protocol is still 
unrestored, it is challenging to draw any conclusions from the results obtained 
from this study. However, given the potential prenatal and neonatal applications 
of AFSCs, there is value in investigating different ways of re-establishing the 
protocol.  
 
Effect of culture conditions on cellular identity 
Although AFSCs have been suggested as a superior stem cell resource for 
potential clinical applications, the in vitro conditions to maintain the primitive 
features of AFSCs has still not yet been standardized. DMEM or α-MEM 
supplemented with various factors is commonly used as a supporting medium. 
However, these media are only suitable for sustaining MSC and not ESC 
properties. Additionally, our previous study has already demonstrated that 82% 
of the transcriptome is similar in AFSCs maintained in an ESC condition 
compared to ESCs. It indicates that primitive AFSCs could be better preserved 
in an ESC niche. In this study, we reveal that both multipotent and pluripotent 
markers are sustained more efficiently and osteogenic differentiation ability is 
enhanced in AFSCs maintained in ESC conditions compared to MSC 
conditions. TGF-β induced CD73 expression plays a part in enhancing 
osteogenic differentiation. These findings suggest ideal culture conditions to 
preserve primitive features of AFSCs in vitro and could potentially have clinical 
application in the future treatment of bone defects. 
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Other factors regulating osteogenesis 
CD73 is not the only target regulated by TGF-β signalling. Alkaline phosphatase 
(AP) is reported as a downstream target of TGF-β. AP is an enzyme that is 
known to play a role in regulating mineralization during osteogenesis [241]. With 
the induction of TGF-β, AP activity and osteogenesis were greatly enhanced 
[242]. Our results also demonstrated that AFSCs maintained in ESC conditions 
showed greater AP activity compared to those grown in MSC conditions, 
confirming the finding of the previous study that the role of TGF-β in ESC 
conditions results in better osteogenesis. However, in this study, we reveal 
another pathway of TGF-β in regulating osteogenesis, indicating that multiple 
factors contribute to osteogenic differentiation. Additionally, TGF-β is not the 
only factor in Nutristem medium to preserve pluripotency of ESCs/iPSCs. 
Although limited information of the components in the media can be obtained, 
there are still some known factors that play pivotal roles in maintaining 
pluripotency, such as bFGF. As described in the previous section, pluripotent 
stem cells can be maintained in a fibroblast-based feeder condition, indicating 
that bFGF is an important factor in the media for sustaining pluripotent stem 
cells. bFGF has been reported in regulating osteogenesis. In bFGF knockout 
mice, a significant decrease in bone volume, mineral apposition, bone formation 
rates, and increase of marrow fat were found. In addition, bone marrow MSCs 
from the knockout mice demonstrated lower osteogenesis with reduced alkaline 
phosphatase activity and mineralization; whereas higher adipogenesis with 
increase of adipogenic markers were found. By supplementing the MSCs from 
the knockout mice with bFGF, osteogenesis was enhanced while adipogenesis 
was inhibited [243, 244]. Although we have established the role of TGF-β/CD73 
in enhancing the osteogenesis of AFSCs from ESC conditions, further studies 
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on other potential factors involved are still necessary to obtain optimal in vitro 
conditions to preserve the osteogenic ability of AFSCs.  
 
Potential cell therapy with AFSCs from ESC conditions 
In addition to the mechanism of osteogenesis in vitro, our lab has previously 
demonstrated that AFSCs maintained in MSC conditions can contribute to bone 
repair after transplantation into the osteogenesis imperfecta (OI) mouse model 
[166]. Following intraperitoneal injection, AFSCs were able to engraft in bone 
and differentiate into osteoblasts. Fracture susceptibility was reduced and bone 
strength and quality were enhanced. Moreover, we also found that AFSCs were 
capable of modulating the inflammatory niche in bone, with effects on TNF-α 
and TGF-β. Our findings suggest that AFSCs sustained in MSC conditions have 
therapeutic effect on bone defects. Similarly, in this study, we show that 
osteogenic ability is enhanced in AFSCs maintained in ESC condition. Further 
research is recommended to investigate whether AFSCs from ESC conditions 
can offer better therapeutic benefits in OI mice compared to AFSCs from MSC 
conditions. If AFSCs maintained in ESC conditions are more effective at 
rescuing bone defects in vivo, it might suggest that sustaining AFSCs in ESC 
condition in vitro could be ideal for targeting bone diseases for the future 
applications.  
 
Wnt-dependent induction of cardiomyocyte differentiation from AFSCs 
In addition to osteogenic differentiation, cardiac differentiation of AFSCs and 
other MSCs has been widely studied. Various differentiation protocols have 
been established, such as direct/indirect co-culture with ventricular myocytes 
and induction with 5-aza treatment. However, with these protocols, AFSCs 
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maintained in MSC conditions have not yet been successfully differentiated into 
cardiomyocytes; cardiac markers are expressed but there is no spontaneous 
contractile activity. As shown in the previous chapter, features of AFSCs can be 
better preserved in ESC conditions. Here, we tested a Wnt-dependent protocol 
for differentiating pluripotent stem cells into fully-differentiated cardiomyocytes, 
combined with the co-culture system and 5-aza, on AFSCs from both conditions. 
Our results showed that, with the Wnt-dependent protocol, expression of 
cardiac markers can be induced more effectively than co-culture or 5-aza alone. 
However, spontaneous contraction is still not observed under any of the above 
conditions, indicating that although primitive features of AFSCs are better 
preserved in ESC conditions, the Wnt-dependent protocol is still not sufficient 
to obtain functional cardiomyocytes from AFSCs. 
 
Optimization of the protocol  
In order to acquire fully differentiated cardiomyocytes from AFSCs or MSCs in 
vitro, further optimization of the protocol is essential. In addition to induction by 
different chemicals, like Wnt and 5-aza, the environmental conditions for 
cardiac induction plays an important role. For instance, structural and 
mechanical properties of scaffolds can promote cardiac differentiation of MSCs. 
By seeding MSCs onto synthetic scaffolds with an electrical field, cardiac 
differentiation can be stimulated. Moreover, stretching the scaffolds can further 
enhance the differentiation, with remarkable increases in cardiac markers and 
developing calcium channels [245]. Stretching can mimic the in vivo conditions 
which the cardiac progenitor cells might be experiencing during differentiation. 
It indicates that mechanical stimulation might also be a pivotal factor for cardiac 
differentiation. Combining chemical and physical stimulation might provide 
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more effective conditions to promote further differentiation of AFSCs.  
 
In addition, as addressed in the previous chapter, forced expression of cardiac 
transcriptional regulators is a way to induce cardiac differentiation. In order to 
investigate whether AFSCs or MSCs are capable of becoming fully 
differentiated cardiomyocytes, forced expression of the key transcription factors 
during cardiac development, such as Mesp1, Nkx2.5, Tbx5 and Gata4, could 
be an alternative method. AFSCs with forced expression of the key transcription 
factors can then be examined for the expression of cardiac markers, 
spontaneous contraction and electrophysiology to observe the level of 
cardiomyocyte maturity which can be obtained. If fully differentiated 
cardiomyocytes can be achieved, it might indicate that AFSCs do have the 
potential to become mature cardiomyocytes and that the optimal protocol has 
not yet been found. However, if it still demonstrates only the increase of cardiac 
markers, AFSCs might only have limited cardiac differentiation ability as shown 
in this and previous studies.  
 
Therapeutic benefits through paracrine effect 
Although AFSCs have, to date, only demonstrated limited cardiac differentiation 
ability, pre-clinical results still show promising therapeutic benefits. For example, 
intramyocardial injection of AFSCs following myocardial infarction has been 
shown to result in preservation of infarcted thickness, higher vascular density, 
and increased survival rate. Moreover, transplanted AFSCs expressed cardiac 
markers, such as troponin, α-actinin, and Nkx2.5 [142]. However, fully 
differentiated cardiomyocytes were still not found. In addition to their 
differentiation ability, AFSCs and other MSCs are also known as niche 
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modulators. By paracrine effects, endogenous repair cells can be recruited to 
the site of injury and adverse inflammatory signal can be neutralized. Applying 
conditioned medium collected from AFSCs to disease models has been shown 
to result in successful treatment. Yoon and colleagues have shown that the 
conditioned medium from AFSCs contained various cytokines and chemokines, 
including different interleukins (IL-6, IL-8 etc.), TGF-β, VEGF, and EGF. With 
the injection of conditioned medium, wound healing by dermal fibroblasts was 
enhanced through TGF-β signalling [246]. Due to the presence of VEGF in the 
conditioned medium, angiogenesis was promoted with higher density of 
vessels to prevent capillary loss and tissue necrosis [247]. Furthermore, 
recruitment of endogenous endothelial progenitors to the injured site to promote 
angiogenesis were found with treatment by conditioned medium [248]. 
Additionally, the presence of anti-inflammatory interleukins in the conditioned 
medium, such as IL-10 and IL-27, suggests AFSCs offer inflammatory 
modulation. Intrahepatic injection with conditioned medium decreased markers 
of liver damage (AST and ALT) and downregulated pro-inflammatory factors 
[249]. The paracrine benefits from AFSCs have been applied to cardiac 
diseases. With the injection of conditioned medium to myocardial infarction 
models, myocardial cell survival and infarct size were both rescued through the 
existence of a cardioprotective factor, Tβ4, in the medium [165]. However, the 
detailed therapeutic mechanism underlying the paracrine effect is still not clear. 
Although several factors have been identified, further studies into the function 
of specific factors and precise concentrations are still needed. Investigation of 
optimal concentration is particularly required, as cells respond to the same 
factor differently with various doses.  
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In order to develop further knowledge of the paracrine effect of AFSCs, we 
recommend comparison of the conditioned medium collected from parental and 
the Wnt-induced differentiated AFSCs maintained in both MSC and ESC 
conditions. It will be interesting to observe if more cardioprotective factors or 
fewer anti-inflammatory factors are present in differentiated cells than parental 
groups. Differences between AFSCs from both MSC and ESC conditions could 
be compared to investigate whether the paracrine effect will also be affected by 
different niche settings. Further studies could offer more details of the effect of 
culture conditions on paracrine therapeutic benefits of AFSCs in cardiac 
diseases.  
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